Medullary Thyroid Cancer (MTC)

Recent articles related to MTC

Published: Dec 4th, 2020 2:45 PM

Genentech's Gavreto scores US approval for RET thyroid cancer

"Roche's Genentech division and its partner Blueprint Medicines have scored a new approval for Gavreto in the US for the treatment of RET-altered ..."

Published: Dec 4th, 2020 5:45 AM

Gavreto Approved for Treatment of RET-Altered Thyroid Cancers

"... Genentech/Blueprint Medicines) for patients aged 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who ..."

Published: Dec 3rd, 2020 8:22 PM

Gavreto Gets Accelerated Approval for RET-Altered Thyroid Cancers

"... RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, or with RET fusion-positive thyroid cancer who require systemic therapy ..."

Published: Dec 3rd, 2020 2:33 AM

FDA Approvals Roundup: Imcivree, Danyelza, Ga 68 PSMA-11

"Gavreto gets expanded indications for RET-altered thyroid cancers. Blueprint Medicines' Gavreto (pralsetinib capsules) has received two new ..."

Published: Dec 3rd, 2020 1:13 AM

Genentech, Blueprint Medicine's Gavreto Receives FDA Approval in RET-Altered Thyroid Cancer

"... second precision medicine option for patients with these types of cancers, following the FDA's approval of selpercatinib (Eli Lilly's Retevmo) in May."

Published: Dec 2nd, 2020 9:54 PM

Roche, Blueprint catch up with Lilly as Gavreto snags FDA thyroid cancer nod

"The FDA has approved Roche and Blueprint Medicines' Gavreto in advanced or metastatic RET-mutant medullary or RET fusion-positive thyroid ..."

Published: Dec 2nd, 2020 4:37 PM

Roche, Blueprint raise pressure on Lilly with new Gavreto approval

"Retevmo (selpercatinib) was simultaneously approved by the agency for the lung and thyroid cancer in May, so has enjoyed an all-too brief period as ..."

Published: Dec 2nd, 2020 3:52 AM

FDA Approves Pralsetinib for Thyroid Cancers Harboring RET Alterations

"On December 1, 2020, the FDA granted approval to pralsetinib (Gavreto, Blueprint Medicines Corporation) for patients with advanced or metastatic ..."

Published: Dec 2nd, 2020 2:22 AM

FDA approves Gavreto for RET-altered thyroid cancers

"Source: Adobe Stock. Pralsetinib (Gavreto, Blueprint Medicines) is a once-daily oral therapy designed to target oncogenic RET alterations. The FDA ..."

Published: Dec 2nd, 2020 1:48 AM

Genentech Announces FDA Approval of Gavreto (pralsetinib) for People With Advanced or ...

"Tumor Lysis Syndrome (TLS): Cases of TLS have been reported in patients with medullary thyroid carcinoma receiving Gavreto. Patients may be at risk ..."

Published: Dec 2nd, 2020 1:26 AM

FDA OKs Blueprint Medicines and Roche's Gavreto for type of medullary thyroid cancer

"Blueprint Medicines (BPMC -2.5%) and collaboration partner Roche (OTCQX:RHHBY +2.1%) announce the FDA nod for Gavreto (pralsetinib) for the ..."

Published: Dec 2nd, 2020 1:01 AM

FDA Approves Blueprint Medicines' Gavreto (Pralsetinib) Capsules, For Oral Use

"FDA Says Approves Gavreto for Treatment of Adult Patients With Metastatic Rearranged During Transfection Fusion-positive Non-small Cell Lung ..."

Published: Dec 1st, 2020 11:20 PM

November UKG Workforce Activity Report: Smaller Businesses Lose Shifts

"Approximately 10-20% of people with papillary thyroid cancer (the most ... RET-mutant medullary thyroid cancer (MTC), RET fusion-positive thyroid ..."

Published: Dec 1st, 2020 3:30 AM

Cabozantinib for Prostate Cancer - A Renewed Hope

"... hepatocellular carcinoma,⁵ and medullary thyroid cancer,⁶ enthusiasm for single-agent use in prostate cancer was lost after the above experience."

Published: Nov 30th, 2020 3:50 PM

Adrenocortical Carcinoma Pipeline, Emerging Therapies and Key Players by DelveInsight

"Cabozantinib is already approved by the US FDA for the treatment of metastatic medullary thyroid cancer, advanced renal cell carcinoma with history ..."

Published: Nov 30th, 2020 12:41 PM

Epirubicin (CAS 56420-45-2) Market 2020 to Flourish with an Impressive CAGR of XX% in the year ...

"... cancer, liver cancer (including primary hepatocytes) Cancer and metastatic cancer) and various solid tumors such as medullary thyroid carcinoma."

Published: Nov 30th, 2020 11:56 AM

Global Cabozantinib Market 2020 2025 Research Report Segment Outlook, Growth Potentials ...

"... market report covers the following segments: , Medullary Thyroid Cancer Treatment, Second Line Treatment for Renal Cell Carcinoma."

Published: Nov 25th, 2020 9:30 PM

Multikinase Inhibitor Options Abound for Patients With RET-Mutant Medullary Thyroid Cancer

"RET aberrations in medullary [thyroid cancer are] mostly point mutations. In papillary thyroid cancer, you can still have point mutations, but it's mostly ..."

Published: Nov 23rd, 2020 7:48 PM

Catalent, Blueprint Enter GAVRETO Commercial Supply Pact

"GAVRETO is a new therapy developed by Blueprint Medicines for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as ..."

Published: Nov 23rd, 2020 7:02 PM

Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval ...

"Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETO (pralsetinib) ..."

Published: Nov 23rd, 2020 6:52 PM

FDA Action Alert: Blueprint, Liquidia, Revance, Rhythm and Merck

"Blueprint Medicines' Pralsetinib for Non-Small Cell Lung Cancer ... 2020 for pralsetinib for locally advanced or metastatic RET fusion-positive ..."

Published: Nov 20th, 2020 7:01 PM

'What you see here now, this is my wife. It feels like we've got her back': Middlesbrough coach ...

"Gemma, 40, was given 12 months to live last year but her brain tumour is now 'stable' after use of a trial drug from Germany; ONC201 costs 5,000 per ..."

Published: Nov 20th, 2020 12:18 AM

Real-World Date Confirm Vandetanib and Cabozantinib Are Effective 1L/2L Treatments for ...

"For the majority of patients with medullary thyroid cancer (MTC), vandetanib (Caprelsa) and cabozantinib (Cabometyx) are both effective treatment ..."

Published: Nov 19th, 2020 9:36 PM

Interesting WRB Put And Call Options For July 2021

"Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations. The approval is for the ..."

Published: Nov 12th, 2020 10:48 PM

Cabozantinib Plus Pembrolizumab May Improve Melanoma Outcomes

"... such as renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. c-MET activation promotes PD-L1 expression, noted Jain."

Published: Nov 12th, 2020 10:14 PM

Philadelphia's 'hungry' cell and gene therapy companies seek more talent, capital to fuel growth ...

"The university spun out companies like Carisma Therapeutics and Tmunity Therapeutics, and research talent flows from the school to startups."

Published: Nov 12th, 2020 9:52 PM

Objective Responses Observed in Rare Thyroid Tumors With Dual Checkpoint Blockade

"The most common thyroid cancer subtype was papillary in 47% of patients, while other subtypes in the cohort included medullary thyroid cancer (MTC; ..."

Published: Nov 6th, 2020 9:18 PM

Exelixis' (EXEL) Q3 Loss Wider Than Expected, Revenues Beat

"Cometriq (cabozantinib capsules) for the treatment of medullary thyroid cancer generated $9 million in net product revenues. Exelixis earned $19.9 ..."

Published: Nov 6th, 2020 2:00 AM

Tmunity to Present at Upcoming Investor Conferences

"Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of ..."

Published: Nov 6th, 2020 12:30 AM

Roles of the RET Proto-oncogene in Cancer and Development

"Moreover, point mutations in RET are responsible for multiple endocrine neoplasia types 2A and 2B, which can develop into medullary thyroid cancer ..."

Published: Oct 31st, 2020 12:07 AM

NIH Starts Clinical Trial with ONC206, a Next-Generation Imipridone

"While DRD2 is also targeted by ONC201, ONC206 exhibits distinct biological effects and chemical properties that position its clinical development in ..."

Published: Oct 29th, 2020 8:56 PM

Blueprint Medicines (BPMC) Q3 Earnings Beat, Revenues Rise Y/Y

"... with various types of RET-altered thyroid cancers and other solid tumors. ... medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer."

Published: Oct 27th, 2020 7:03 PM

Pralsetinib and Selpercatinib Expand the RET+ NSCLC Paradigm

"Justin F. Gainor, MD, discusses the recent FDA approvals of pralsetinib and selpercatinib, which led to expanded treatment options for patients with non ..."

Published: Oct 27th, 2020 3:49 PM

Lilly Reports Third-Quarter Financial Results, Updates Guidance

"... Verzenio, Jardiance, Olumiant, Emgality, Tyvyt, Baqsimi, Cyramza, Retevmo and Basaglar contributed nearly 9 percentage points of revenue growth ..."

Published: Oct 26th, 2020 8:56 PM

Triple meeting the point of turning to TPX-0022

"However, TPX-0022 hits two additional kinases involved in tumour ... assets Turning Point is now highlighting include TPX-0046, a Ret inhibitor to rival ..."

Published: Oct 24th, 2020 7:15 PM

Turning Point Therapeutics Announces Pricing of $400 Million Public Offering of Common Stock

"... a Phase 1 study called SHIELD-1 in patients with advanced or metastatic solid tumors harboring genetic alterations in MET; RET inhibitor TPX-0046, ..."

Published: Oct 24th, 2020 2:00 PM

Thyroid cancer: Cushing syndrome is a lesser-known warning sign what is it?

""Medullary carcinoma of the thyroid is also probably related to this group of tumours. It is suggested that the great majority of the tumours associated with ..."

Published: Oct 23rd, 2020 1:25 AM

Pralsetinib

"Pralsetinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion- positive non- ..."

Published: Oct 21st, 2020 9:18 PM

The Alliance for Regenerative Medicine Announces Election of 2021 Officers, Executive Committee ...

"Usman 'Oz' Azam, M.D. President and CEO, Tmunity Therapeutics (Vice Chairman). Amy Butler, Ph.D. President, Biosciences, Thermo Fisher ..."

Published: Oct 21st, 2020 5:00 PM

Turning Point Therapeutics Announces Abstract For TRIDENT-1 Clinical Study of Repotrectinib ...

"... TPX-0046, targeting RET and SRC, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic ..."

Published: Oct 19th, 2020 5:11 PM

Orphan Drugs Market to Witness Massive Growth by 2027 | Top Players Hoffmann-La Roche Ltd ...

"... Gaucher disease type 1 (GD1), Metastatic medullary thyroid carcinoma, Advanced gastric cancer or gastro-esophageal junction adenocarcinoma, ..."

Published: Oct 19th, 2020 1:03 AM

VIDEO: Surgeon shares pearls for new drug delivery options

"Blueprint's Positive Pralsetinib Data Places New Option on Horizon for RET-Altered Cancer Patients. Precision Oncology News, 2020. Single-Cell ..."

Published: Oct 19th, 2020 12:30 AM

Hunting Resistance Mechanisms in RET-Fusion Lung Cancer

"Pralsetinib is a potent and selective TKI that targets RET alterations, which drive roughly 1%-2% of NSCLC cases, and was designed to have limited ..."

Published: Oct 15th, 2020 11:45 PM

TRK Fusions Help to Fulfill Unmet Need in Thyroid Cancer Treatment Landscape

"TRK fusions have not been observed in medullary thyroid cancer, however, limiting use of larotrectinib (Vitrakvi), a TRK inhibitor, to patients with DTC ..."

Published: Oct 15th, 2020 9:07 PM

A Phase II Study of Cabozantinib, Nivolumab, and Ipilimumab Immunotherapy in Patients with ...

"Cabozantinib inhibits an enzyme called tyrosine kinase which can fuel cancer growth; it is already used to treat medullary thyroid cancer. Nivolumab ..."

Published: Oct 15th, 2020 6:18 PM

Endocrine Update 2021 - LIVESTREAM

"... medullary thyroid cancer; current and recently approved systemic treatment ... of bone loss after bariatric surgery to prevent metabolic bone disease."

Published: Oct 14th, 2020 7:48 PM

RET Inhibitor Enters the Therapeutic Ring in Multiple Settings

"Selpercatinib (Retevmo) joins the ranks of therapies approved for several tumor types, with indications for patients with nonsmall cell lung cancer ..."

Published: Oct 14th, 2020 5:56 PM

ESMO Data Show Benefit of Approved Thyroid Cancer Regimens in Select Patients

"The key takeaway from these data were that testing for NTRK gene fusions should be routine for patients with non-medullary, advanced thyroid cancer ..."

Published: Oct 13th, 2020 9:07 PM

Selpercatinib Data Underscore Value of Precision Medicine in RET-Driven Lung Cancer

"The LIBRETTO-001 study demonstrated promising activity with selpercatinib, the selective RET inhibitor, as treatment of patients with RET-mutant ..."

Published: Oct 13th, 2020 5:17 PM

Hainan's Lecheng begins to sell top-notch US cancer drug

"According to the news outlet, the drug is called pralsetinib and it is extremely effective in the treatment of non-small cell lung cancer. The Food and ..."

Published: Oct 13th, 2020 4:37 AM

YOUR HEALTH: One young man saved from a rare cancer

"Tanner had stage four medullary thyroid cancer. Doctors tried every treatment available but nothing worked. "It was going to be hospice," said Cleveland ..."

Published: Oct 13th, 2020 2:33 AM

Patient-Reported Outcomes Confirm Tolerability of Selpercatinib in RET-Driven Thyroid Cancer

"... with RET-altered medullary thyroid cancer (MTC) or advanced thyroid cancer. These findings ultimately led to the FDA approval of this RET inhibitor, ..."

Published: Oct 9th, 2020 10:41 PM

Teacher who was diagnosed with thyroid cancer at age 21 and had 100 tumors in her lungs - but ...

"An ultrasound led to a diagnosis of medullary thyroid cancer. Doctors then performed surgery to remove her thyroid and 42 lymph nodes. Ashley Wyss ..."

Published: Oct 9th, 2020 1:26 PM

Teacher with 100 cancerous tumours in her lungs who refused to live in fear dies

""She will be remembered for her positivity, kindness, and strength during her nine-year battle with medullary thyroid cancer. A tumour resulted in Ashley ..."

Published: Oct 8th, 2020 1:26 AM

Immune co-inhibitory receptors PD-1, CTLA-4, TIM-3, LAG-3 and TIGIT in medullary thyroid ...

"Researchers analyzed a large cohort of medullary thyroid carcinomas ... coexpression were identified as promising biomarkers for tumor recurrence, ..."

Published: Oct 7th, 2020 5:33 PM

Cancer is Still the Real Global Health Crisis Four Stocks with Answers (EXEL, BMY, NBIO, MRK)

"... the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, ..."

Published: Oct 6th, 2020 6:07 PM

Selpercatinib Induces Infrequent Hypersensitivity in RET Fusion-Positive NSCLC, Analysis Shows

"Selpercatinib (LOXO-292)-related hypersensitivity reactions occurred infrequently in patients with RET fusion-positive nonsmall cell lung cancer ..."

Published: Oct 3rd, 2020 2:24 AM

Untargeted longitudinal analysis of a wellness cohort identifies markers of metastatic cancer years ...

"CALCA, a biomarker for medullary thyroid cancer, was hypersecreted in metastatic pancreatic cancer at least 16.5 months pre-diagnosis. ERBB2 ..."

Published: Oct 2nd, 2020 11:56 PM

A Look Back at the FDA News from September 2020

"... of patients with advanced or metastatic RET-mutant medullary thyroid cancer as well as for patients with RET fusionpositive thyroid cancer."

Published: Oct 2nd, 2020 6:30 PM

US FDA approval tracker: September

"Roche will co-commercialise Gavreto with Blueprint in the US after paying $650m up front for rights. Elsewhere, Glaxosnithkline's Nucala became the ..."

Published: Oct 1st, 2020 8:33 PM

Fast Five Quiz: Thyroid Cancer Practice Essentials

"Most thyroid cancers are papillary carcinomas, with follicular carcinomas, medullary thyroid carcinomas, and anaplastic carcinomas accounting for far ..."

Published: Oct 1st, 2020 8:00 PM

NSCLC Treatment Portfolio Gains RET-Targeted Therapy

"Results showed that pralsetinib elicited durable responses, with 57% and 70% of patients with previously treated and treatment-nave disease ..."

Published: Sep 30th, 2020 6:07 PM

Turning Point Therapeutics to Participate in Upcoming Virtual Investor Conference

"... patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET and SRC, which is being studied in ..."

Published: Sep 29th, 2020 10:37 PM

10 recent exec moves affecting the pharma industry

"Philadelphia-based drugmaker Tmunity named Johnson & Johnson and GlaxoSmithKline veteran Vijay Reddy, MD, its new chief research and ..."

Published: Sep 29th, 2020 9:28 PM

Blueprint Medicines Rises YTD on Robust Ayvakit Progress

"Both companies will co-commercialize Gavreto in the United States while Roche alone will commercialize the drug outside the United States. Story ..."

Published: Sep 29th, 2020 9:18 PM

Blueprint Medicines Rises YTD on Robust Ayvakit Progress

"Further, the FDA granted a Priority Review to Gavreto for the treatment of advanced/metastatic RET-mutant medullary thyroid cancer (MTC) and RET ..."

Published: Sep 29th, 2020 7:48 PM

The window of opportunity opens wider for Ascendis

"This aims to overcome Natpara's problem variable PTH levels; Natpara was also associated with calcium imbalances, and carried a black box ..."

Published: Sep 29th, 2020 3:52 PM

Tmunity to Present at Upcoming Investor Conferences - Sep 29, 2020

"Tmunity is a private, clinical-stage biotherapeutics company, focused on saving and improving lives by delivering the full potential of next-generation T- ..."

Published: Sep 28th, 2020 7:55 PM

Clinical trial of selpercatinib shows strong response for patients with non-small cell lung cancer

"... medullary thyroid cancer who require systemic therapy, and c) patients 12 and older with advanced or metastatic RET-fusion positive thyroid cancer ..."

Published: Sep 28th, 2020 7:15 PM

Clinical trial of selpercatinib shows strong response for patients with non-small cell lung cancer

"Singapore, 28 September 2020 - An international team of researchers has found that selpercatinib, a drug that precisely targets cancers driven by ..."

Published: Sep 28th, 2020 5:33 PM

Targeted therapy found to be effective at shrinking tumors in patients with nonsmall-cell lung cancer

"... lung cancer, b) adults and children 12 and older, with advanced or metastatic RET-mutated medullary thyroid cancer who require systemic therapy, ..."

Published: Sep 28th, 2020 5:02 PM

Clinical Trial of Selpercatinib Shows Strong Response for Patients with Non-Small Cell Lung Cancer

"Singapore, 28 September 2020 An international team of researchers has found that selpercatinib, a drug that precisely targets cancers driven by ..."

Published: Sep 27th, 2020 12:41 AM

Tmunity to Present at Upcoming Investor Conferences

"Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of ..."

Published: Sep 26th, 2020 2:11 AM

Healthy Living: Retevmo for Thyroid Cancer

"... in May for people with non-small cell lung cancer, and two types of thyroid cancer with specific gene mutations, including medullary thyroid cancer."

Published: Sep 24th, 2020 7:15 PM

Study: Pralsentinib May Be an Effective Treatment for RET Mutation-Positive Medullary Thyroid ...

"Pralsetinib (BLU-667) shows promise as an effective treatment for patients with advanced RET mutation-positive medullary thyroid cancer (MTC), ..."

Published: Sep 23rd, 2020 7:48 PM

Gavreto (pralsetinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

"Gavreto (pralsetinib) is a targeted therapy indicated for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small ..."

Published: Sep 23rd, 2020 4:48 AM

Positive top-line data drive Blueprint toward an sNDA

"This rare disease is often undiagnosed or misdiagnosed, according to ... in RETm medullary thyroid cancer and RET fusion-positive thyroid cancer by ..."

Published: Sep 21st, 2020 11:11 PM

Larotrectinib Induces Promising Response Rate in Patients With Differentiated Thyroid Cancer

"These findings indicate that routine testing for NTRK gene fusions should be considered in patients with non-medullary advanced thyroid cancer as this ..."

Published: Sep 21st, 2020 8:22 PM

Blueprint Medicines says durable clinical benefits observed for Gavreto in thyroid cancer

"GAVRETO was well-tolerated, and overall, treatment-related adverse events were primarily mild to moderate. Investigator-reported serious/servere ..."

Published: Sep 21st, 2020 5:00 PM

Thyroid Cancer: Small Gland, Big Impact

"There are four main types of thyroid cancer (papillary, follicular, medullary and anaplastic). Luckily, most types of thyroid cancer are very treatable and ..."

Published: Sep 21st, 2020 2:22 AM

Ongoing ARROW Trial Data Support Pralsetinib as a Potential Treatment Option in RET-Mutant MTC

"Patients with medullary thyroid cancer (MTC) harboring abberations in RET who were treated with pralsetinib (Gavreto) across therapy lines exhibited ..."

Published: Sep 21st, 2020 12:41 AM

Pralsetinib Active in RET-Mutant Advanced Medullary Thyroid Cancer

"Potent and durable clinical activity was shown with pralsetinib (Gavreto) as treatment of patients with RET-mutant advanced medullary thyroid cancer ..."

Published: Sep 20th, 2020 5:22 PM

Blueprint Medicines Reports ARROW Trial Data at ESMO Virtual Congress 2020 Demonstrating ...

"GAVRETO demonstrated broad clinical activity in patients with RET-mutant MTC with or without prior systemic therapy. In 53 patients previously treated ..."

Published: Sep 20th, 2020 2:00 PM

Progress in treating medullary thyroid cancer

"Recently, there has been tremendous progress made in treating this disease with targeted therapy. We recently spoke with Mimi Hu, M.D., to learn more..."

Published: Sep 18th, 2020 10:37 PM

Turning Point Therapeutics to Participate in HC Wainwright Precision Oncology Investor Conference

"... TPX-0046, targeting RET and SRC, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic ..."

Published: Sep 16th, 2020 6:18 PM

Best Life: New drug controls rare cancers with gene mutation

"But for those with medullary thyroid cancer, a rare form of the disease, there have been few effective options. Now, introducing the first young man in ..."

Published: Sep 16th, 2020 2:14 AM

Selpercatinib

"Reduce selpercatinib dose in patients with severe hepatic impairment. Consult manufacturer's labeling for recommended dosage modifications for ..."

Published: Sep 15th, 2020 2:56 AM

From natural killer cells to off-the-shelf CAR-Ts, biopharma targets cancer with next-gen cell ...

"This month, Tmunity Therapeutics expects to finish enrolling an early clinical trial testing an engineered CAR-T immune cell therapy for metastatic ..."

Published: Sep 15th, 2020 2:00 AM

Benefits and limitations of TKIs in patients with medullary thyroid cancer: A systematic review and ...

"... meta-analysis, researchers documented clinical response and toxicities of tyrosine kinase inhibitors (TKIs) in advanced medullary thyroid carcinoma ..."

Published: Sep 13th, 2020 4:47 PM

Data Shows That Workers Are Waiting Much Too Long to Start Saving for Retirement

"... of proteins known to drive aggressive tumor growth for around 1% to 2% of all cases of NSCLC, and around 60% of all medullary thyroid cancers."

Published: Sep 13th, 2020 4:37 PM

Is Blueprint Medicines a Good Biotech Stock to Buy Now?

"... and around 60% of all medullary thyroid cancers. In a clinical trial leading to its approval, Gavreto shrank tumors for 70% of treatment-naive NSCLC ..."

Published: Sep 13th, 2020 3:18 PM

Look back at pharma news in the week to September 11, 2020

"In conjunction of the Gavreto approval in NSCLC, Blueprint also announced that the FDA has accepted pralsetinib new drug application (NDA) in RET- ..."

Published: Sep 11th, 2020 11:11 PM

Pralsetinib receives FDA approval for lung cancer with RET gene fusions

"... cancer types, including NSCLC and medullary thyroid cancer, and treatment options that selectively target these genetic alterations are limited."

Published: Sep 11th, 2020 9:07 PM

FDA Approves Oncomine Dx Target Test Companion Diagnostic for Pralsetinib in RET+ NSCLC

"Specifically, pralsetinib elicited an overall response rate (ORR) of 57% (95% CI, 46%-68%) and a complete response (CR) rate of 5.7% in 87 ..."

Published: Sep 11th, 2020 6:39 PM

GSK and J&J alum Vijay Reddy to take control of R&D at Tmunity; Andrew Hirsch exits Agios for ...

"Tmunity also added to their leadership team by selecting Simona King as their CFO. A nearly 20-year vet of Bristol Myers Squibb in various financial ..."

Published: Sep 11th, 2020 2:51 AM

Health Beat: RETEVMO for thyroid cancer saves man's life

"Ninety percent of all patients are cured if it's caught early, but for those with medullary thyroid cancer, a rare form of the disease, there have been few ..."

Published: Sep 11th, 2020 1:48 AM

FDA Approves Gavreto for Treatment of RET-Positive, Metastatic NSCLC

"The FDA granted accelerated approval to pralsetinib (Gavreto, Blueprint Medicines) for adults with metastatic RET fusionpositive non-small cell lung ..."

Published: Sep 11th, 2020 12:28 AM

Health Beat: RETEVMO for thyroid cancer saves man's life

"Andersen used RETEVMO on Tanner, who was 17. Within a few treatments, Tanner's tumors began to shrink. "My goal was to finish high school and at ..."

Published: Sep 10th, 2020 5:11 PM

Retevmo for thyroid cancer

"RETEVMO was approved in May for people with non-small cell lung cancer, and two types of thyroid cancer with specific gene mutations, including ..."

Published: Sep 10th, 2020 11:12 AM

Gavreto (pralsetinib)

"Medscape - Non-small cell lung cancer dosing for Gavreto (pralsetinib), frequency-based adverse effects, comprehensive interactions, ..."

Published: Sep 10th, 2020 2:33 AM

Lymph node metastasis in hereditary medullary thyroid cancer is independent of the underlying

"Although the onset of hereditary medullary thyroid cancer (MTC) depends on mutational risk, researchers sought to analyze the impact of this risk on ..."

Published: Sep 9th, 2020 9:30 PM

FDA Approvals Roundup: Gavreto and Trulicity

"Gavreto approved for metastatic lung cancer with RET gene fusions ... medullary thyroid cancer and RET fusion-positive thyroid cancer, which are also ..."

Published: Sep 9th, 2020 8:56 PM

FDA Clears Targeted Therapy, Diagnostic for Metastatic RET Fusion-Positive NSCLC

"Pralsetinib (Gavreto), developed by Blueprint Medicines, received accelerated approval. Thermo Fisher Scientific's Oncomine Dx Target Test received ..."

Published: Sep 8th, 2020 7:26 PM

Pralsetinib: Second Drug for RET+ NSCLC Approved in US

"Selpercatinib is also indicated for use in RET+ NSCLC and was approved for use RET+ medullary thyroid cancer and RET+ thyroid cancer."

Published: Sep 8th, 2020 4:40 PM

UPDATED: Roche nabs an FDA OK for Gavreto, triggering a heavyweight bout with rivals at Eli Lilly

"Four months after Eli Lilly's Retevmo got the first FDA OK to treat RET-altered tumors, Roche and Blueprint Medicines are stepping into the ring with ..."

Published: Sep 8th, 2020 11:50 AM

Roche joins competition in new targeted therapy for NSCLC

"The Retevmo trial also showed that 10 out of 11 previously treated NSCLCL patients with brain metastases had intracranial responses (CNS ORR), and ..."

Published: Sep 8th, 2020 4:48 AM

FDA Approves Gavreto for RET Fusion Lung Cancer

"Gavreto (formerly known as BLU-667), developed by Blueprint Medicine in collaboration with Genentech, inhibits a receptor tyrosine kinase known as ..."

Published: Sep 7th, 2020 9:52 PM

II-VI Sell-Off is an Overreaction, Says Five-Star Analyst

"... chemotherapy and for RET mutation-positive medullary thyroid cancer (MTC) that requires systemic treatment and for which there are no acceptable ..."

Published: Sep 7th, 2020 8:45 PM

FDA OKs Blueprint/Roche's Gavreto As Rival To Lilly's Retevmo

"... transfection (RET) fusion-positive non-small cell lung cancer, setting the stage for a head-to-head battle for market share with Eli Lilly's Retevmo."

Published: Sep 7th, 2020 4:15 PM

Blueprint and Roche take on Lilly as FDA approves RET-targeting lung cancer drug

"Approval sets up a rivalry with Eli Lilly's RET inhibitor Retevmo (selpercatinib), and the verdict from experts at this year's American Society of Clinical ..."

Published: Sep 7th, 2020 3:40 PM

Illuminating Hrthle cell carcinoma

"The selective RET kinase inhibitor, selpercatinib (Retevmo; Eli Lilly [NYSE: LLY]), also known as LOXO-292, has been shown to have robust ..."

Published: Sep 7th, 2020 1:48 PM

FDA approves Roche's Gavreto to treat metastatic RET fusion-positive NSCLC

"... (RET) fusion-positive NSCLC, RET-mutant medullary thyroid cancer (MTC), RET fusion-positive thyroid cancer and other RET-altered solid tumours."

Published: Sep 7th, 2020 9:10 AM

Fundraiser for University of Reading law student with cancer to get ONC201 drug

"Fundraiser for University of Reading law student with cancer to get ONC201 drug. By Celine Byford Trainee Reporter. (4). Skip to next photo. 1/4."

Published: Sep 7th, 2020 9:07 AM

Fundraiser for University of Reading law student with cancer to get ONC201 drug

"Fundraiser for University of Reading law student with cancer to get ONC201 drug. By Celine Byford. (3). Skip to next photo. 1/3. Show caption. 1/3."

Published: Sep 5th, 2020 9:18 PM

Exelixis (EXEL) Down 9.4% Since Last Earnings Report: Can It Rebound?

"Cometriq (cabozantinib capsules) for the treatment of medullary thyroid cancer generated $5.1 million in net product revenues. Exelixis earned $16.3 ..."

Published: Sep 5th, 2020 7:37 AM

FDA Grants Priority Review to Pralsetinib for RET+ Thyroid Cancers

"The FDA has granted a priority review to pralsetinib for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer as ..."

Published: Sep 5th, 2020 6:30 AM

Blueprint, Roche take on Lilly with FDA approval for RET cancer drug Gavreto

"It was only May when Eli Lilly's Retevmo became the first FDA-approved drug for RET-altered tumors. Now, a rival therapy has arrived with a better ..."

Published: Sep 5th, 2020 6:07 AM

FDA Approves Pralsetinib in RET Fusion-Positive NonSmall Cell Lung Cancer

"The FDA has approved pralsetinib (formerly BLU-667, Gavreto) for the treatment of adult patients with metastatic RET fusionpositive nonsmall cell ..."

Published: Sep 5th, 2020 3:52 AM

Genentech Announces FDA Approval of Gavreto (pralsetinib) for the Treatment of Adults With ...

"RET-activating fusions and mutations are key disease drivers in many cancer types, including NSCLC and medullary thyroid cancer (MTC), and ..."

Published: Sep 2nd, 2020 11:56 PM

Selpercatinib Demonstrates Durable Efficacy and Intracranial Activity in RET+ NSCLC

"The RET inhibitor selpercatinib (LOXO-292; Retevmo) was shown to have durable efficacy with mostly low-grade adverse effects (AEs) in patients with ..."

Published: Sep 2nd, 2020 11:33 PM

Expert Highlights Major Advancements in Honor of Thyroid Cancer Awareness Month

"In addition, another RET inhibitor, pralsetinib (BLU-667), is also appearing promising for the treatment of RET-mutant MTC and papillary thyroid cancer ( ..."

Published: Sep 2nd, 2020 9:07 PM

RET Inhibitor Demonstrates Efficacy in RET-Altered Thyroid Cancer

"RET alterations are present among 70% of patients with in medullary thyroid cancers (MTC) and 10% of other thyroid cancers, but RET-specific ..."

Published: Sep 2nd, 2020 6:52 PM

BMS oncology chief Namouni lands at Blueprint Medicines to lead R&D

"Fouad Namouni, M.D., arrives after Roche forked over $775 million in cash and equity for the rights to pralsetinib outside the U.S. and China."

Published: Sep 2nd, 2020 4:25 PM

Another Big Pharma 'lifer' in the top ranks of R&D is starting a new chapter in biotech

"Namouni will likely be coming on board just one step ahead of an approval for pralsetinib, Blueprint's RET rival to Eli Lilly's Retevmo, which got out in ..."

Published: Aug 29th, 2020 11:00 PM

New Lung, Thyroid Cancer Tx; COVID Risk in Cancer: It's TTHealthWatch!

"In the thyroid cancers, they had 55 patients with the medullary thyroid cancer previously treated. Sixty-nine percent had a response to the agent with 82 ..."

Published: Aug 28th, 2020 10:37 PM

Adults With Rare Blood Cancers Can Now Receive Treatment From Home

"... as mutation or fusion, in the RET gene, and it is able to treat non-small cell lung cancer, medullary thyroid cancer, and other types of thyroid cancers."

Published: Aug 28th, 2020 8:56 PM

LIBRETTO-001 Trial Shows Promise for Selpercatinib in NSCLC Marked by RET Gene Fusions

"Results from this trial observed in patients with RET-altered lung and thyroid cancers also led to the approval of selpercatinib by the FDA in May for ..."

Published: Aug 28th, 2020 7:48 PM

Trending News on Targeted Oncology, Week of August 28, 2020

"Selpercatinib demonstrated durable efficacy as treatment of patients with medullary thyroid cancer harboring the RET mutation whether or not they ..."

Published: Aug 27th, 2020 7:26 PM

Selpercatinib may provide an effective response against RET-mutated thyroid cancer

"Selpercatinib, a highly selective RET kinase inhibitor, was effective in antitumor activity against medullary thyroid cancer. 2. Selpercatinib caused ..."

Published: Aug 27th, 2020 7:03 PM

Inqovi available for blood cancer patients to receive at home through AllianceRx Walgreens Prime

"Specifically, Retevmo treats three types of tumors non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers in ..."

Published: Aug 27th, 2020 5:56 PM

Selpercatinib Induced Durable Efficacy in RET Fusion-Positive NSCLC

"... which evaluated selpercatinib (formerly known as LOXO-292; Retevmo) as treatment of patients with RET fusion-positive nonsmall cell lung cancer ..."

Published: Aug 27th, 2020 3:41 PM

New England Journal of Medicine Publishes Phase 1/2 Data for Retevmo (selpercatinib) in ...

"Across the 162 Retevmo-treated patients with RET-mutant MTC and RET fusion-positive thyroid cancers, the most common grade 3 adverse events ..."

Published: Aug 27th, 2020 2:59 PM

Selpercatinib Shows Durable Efficacy in RET Fusionpositive NSCLC

"Selpercatinib is a novel, ATP-competitive, highly selective small-molecule inhibitor of RET kinase. Selpercatinib was designed to penetrate the central ..."

Published: Aug 27th, 2020 2:11 AM

Selpercatinib May Be New Standard of Care for RET-Altered Thyroid Cancers, Study Shows

"Researchers suggest that the void could potentially be filled with selpercatinib (formerly known as LOXO-292; Retevmo). Selpercatinib is the first ..."

Published: Aug 27th, 2020 2:00 AM

New Targeted Lung Cancer Drug, Retevmo, So Effective It Gave Musician His Life Back

"RET+ lung cancers are aggressive and have a poor prognosis, but new targeted drug selpercatinib (Retevmo) benefits more than 90% of patients who ..."

Published: Aug 27th, 2020 1:48 AM

Efficacy of Selpercatinib in RET FusionPositive NonSmall-Cell Lung Cancer

"Selpercatinib had durable efficacy, including intracranial activity, with mainly low-grade toxic effects in patients with RET fusionpositive NSCLC who ..."

Published: Aug 26th, 2020 11:56 AM

Debiopharm's New Generation Radionuclide Therapy Advances Into Clinical Research In The ...

"This targeted, theragnostic compound is being researched in various cancer types including advanced Medullary Thyroid Cancer (MTC) and SCLC."

Published: Aug 24th, 2020 5:01 PM

Tri-Cities hockey league, gamers join forces for 5th-grader fighting rare cancer

"When he came in for imaging tests, they discovered medullary thyroid cancer. That form of cancer accounts for just 1 to 2 percent of the already ..."

Published: Aug 20th, 2020 2:00 AM

Selpercatinib Aimed at RET-Altered Cancers

"Selpercatinib Aimed at RET-Altered Cancers. List of authors. Razelle Kurzrock, M.D.. August 27, 2020. N Engl J Med 2020; 383:868-869"

Published: Aug 18th, 2020 7:26 PM

Vandetanib confers clinical benefit for certain patients with medullary thyroid cancer

""Medullary thyroid cancer is a rare neuroendocrine malignancy that derives from parafollicular cells of the thyroid gland that secrete the polypeptide ..."

Published: Aug 15th, 2020 12:41 AM

What Are the Warning Signs of Thyroid Cancer?

"Medullary thyroid cancer: Medullary thyroid cancer arises in the C cells in the thyroid gland. C cells produce a hormone called calcitonin. Elevated levels ..."

Published: Aug 11th, 2020 11:50 AM

Thyroid cancer cells signs and symptoms: What are the signs of thyroid cancer?

"Medullary thyroid carcinoma cn run in fmilies, nd npestic thyroid crcinom is extremely rre nd normlly found in people over 60."

Published: Aug 7th, 2020 8:13 PM

Exelixis' (EXEL) Q2 Earnings and Revenues Surpass Estimates

"Cometriq (cabozantinib capsules) for the treatment of medullary thyroid cancer generated $5.1 million in net product revenues. Exelixis earned $16.3 ..."

Published: Aug 6th, 2020 8:20 PM

Neuroendocrine Tumors Market 2020-2026 Emerging Trends | Major Giants Ipsen Pharma ...

"Carcinoid tumors in the lungs; Pancreatic neuroendocrine tumors; Medullary thyroid carcinoma; Merkel cell carcinoma; Pheochromocytoma of the ..."

Published: Aug 3rd, 2020 5:00 PM

A 67-Year-Old Woman With Differentiated Thyroid Cancer

"Those 2 diagnoses are anaplastic, or undifferentiated thyroid cancer. Then the other diagnosis is medullary thyroid cancer. Transcript edited for clarity."

Published: Jul 31st, 2020 8:22 PM

Blueprint Medicines' (BPMC) Q2 Earnings Miss, Revenues Beat

"Blueprint Medicines and Roche will co-develop pralsetinib globally in RET-altered solid tumors, including non-small cell lung cancer (NSCLC), ..."

Published: Jul 31st, 2020 12:41 AM

Medullary Thyroid Carcinoma in a Patient with MEN 1 Syndrome. Case Report and Literature Review

"Abstract: Medullary thyroid cancer (MTC) is typically associated with multiple endocrine neoplasia type 2 syndrome (MEN 2), but not with multiple ..."

Published: Jul 30th, 2020 4:03 PM

Blueprint Medicines Reports Second Quarter 2020 Financial Results

"Reported updated data from the ongoing ARROW clinical trial of pralsetinib in RET fusion-positive non-small cell lung cancer (NSCLC), thyroid cancer ..."

Published: Jul 30th, 2020 3:18 PM

Lilly Reports Second-Quarter Financial Results, Raises EPS Guidance

"Other notable recent events include FDA approvals for Retevmo, Lyumjev and Tauvid, new approved indications for Taltz and Cyramza, as well as ..."

Published: Jul 29th, 2020 1:37 AM

Phosphoprotein biomarkers to guide cancer therapy are identified

"To find biomarkers, the researchers first used a unique mouse model of medullary thyroid carcinoma, or MTC, whose growth of the tumor can be ..."

Published: Jul 28th, 2020 11:56 PM

License to Pill: Biotech and pharma deals from July 11-July 24

"... for treating RET-altered non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancer, as well as other solid tumors."

Published: Jul 28th, 2020 2:45 PM

Aviation Active Noise and Vibration Control System Market Trend Shows A Rapid Growth By 2026 ...

"Medullary Thyroid Cancer Treatment Market 2020 Global Future Growth| Size, Share, Demand, Regional Trends, Segmentation and Forecasts to ..."

Published: Jul 25th, 2020 1:15 PM

Dil Bechara: What Ailed Kizzie Basu? Here's All You Need To Know About Thyroid Cancer

"Types of Thyroid cancer include Papillary thyroid cancer, Follicular thyroid cancer, Anaplastic thyroid cancer, and Medullary thyroid cancer. These types ..."

Published: Jul 24th, 2020 12:07 AM

SEngine Organoid Testing Leads to Treatment Change for Two Metastatic Colorectal Cancer ...

"... to the multi-tyrosine kinase inhibitor vandetanib (Sanofi/Genzyme's Caprelsa), currently approved for medullary thyroid cancer, but noted no disease ..."

Published: Jul 23rd, 2020 6:52 PM

Lilly's Patient Centric Approach Speeds Treatments To Patients

"Retevmo entered clinical testing in May of 2017 and received FDA approval less than three years later. Jacob Van Naarden, COO for Loxo Oncology at ..."

Published: Jul 22nd, 2020 1:03 PM

Pulmonary function in patients with multiple endocrine neoplasia 2B

"... characterize pulmonary function among patients encountering multiple endocrine neoplasia type 2B (MEN2B). Experts analyzed pulmonary function ..."

Published: Jul 22nd, 2020 3:52 AM

Industry News: Roche collaborates with Blueprint Medicines to bring a new treatment to people ...

"... RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other types of thyroid cancer, as well as other solid tumors."

Published: Jul 22nd, 2020 1:37 AM

The Oncologist's Role With Savvy Patients

"It's long been associated with thyroid cancer, particularly medullary thyroid cancer, but now it's been found through deeper and deeper genomics in a ..."

Published: Jul 21st, 2020 1:14 AM

FDA Approval Insights: Selpercatinib in RET+ NSCLC and Thyroid Cancers

"... treatment of patients with RET alterationpositive nonsmall cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and other thyroid cancers."

Published: Jul 20th, 2020 11:33 PM

Cabozantinib Market Emerging Trends, Strong Application Scope, Size, Status, Analysis and ...

"Medullary Thyroid Cancer Treatment; Second Line Treatment for Renal Cell Carcinoma. Details specified in the document: Consumption graphs of all ..."

Published: Jul 19th, 2020 5:45 PM

Look back at pharma news in the week to July 17, 2020

"Roche was also in the news for its collaboration with Blueprint Medicines on the development of the US biotech's targeted cancer candidate pralsetinib."

Published: Jul 17th, 2020 9:52 PM

Trending News on Targeted Oncology, Week of July 17, 2020

"... in progression-free survival in patients with symptomatic and progressive medullary thyroid cancer in a post-hoc analysis of the phase III ZETA trial."

Published: Jul 17th, 2020 2:33 AM

Targeted oncogene therapy before surgery in pediatric patients with advanced invasive thyroid ...

"Mostly pediatric patients with thyroid cancer initially present with operable disease, however, there are some ... the response to therapy and long-term tolerance in patients with widely invasive medullary thyroid cancer, in whom the ..."

Published: Jul 16th, 2020 1:15 PM

Father Admits 'Helping' With Son's Prizewinning Cancer Project

"A high schooler from the southwestern municipality of Chongqing won first prize in the 34th CASTIC for her research on medullary thyroid cancer, ..."

Published: Jul 15th, 2020 5:45 PM

Blueprint Medicines Corporation Collaborates Roche as (BPMC) soars 3.60% in a week

"Pralsetinib is an investigational once-daily oral precision therapy that is used to treat cancer patients driven by oncogenic RET alterations. Under the ..."

Published: Jul 15th, 2020 4:37 PM

Roche pays $775m upfront to access Blueprint's RET programme

"... fusion-positive non-small cell lung cancer (NSCLC), RET mutation-positive medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer."

Published: Jul 15th, 2020 4:15 PM

Roche-Blueprint ink licensing and collaboration deal for pralsetinib

"Pralsetinib is a once-daily, investigational oral precision therapy offered by Blueprint, which has been used for the treatment of patients with RET-altered ..."

Published: Jul 15th, 2020 11:56 AM

AZN, IQV Team Up To Accelerate COVID-19 Vaccine Work, RIGL's ITP Drug Repurposed, IMV On ...

"In addition, a safety trial in dry eye disease patients is expected to be ... cancer, medullary thyroid cancer, other thyroid cancers, and other solid tumors."

Published: Jul 15th, 2020 2:33 AM

Roche Invests in Blueprint Medicines, Maker of RET Inhibitor Pralsetinib

"... medullary thyroid cancer (MTC) and RET fusionpositive thyroid cancers. ... "Beyond lung cancer, pralsetinib's tumour-agnostic potential further ..."

Published: Jul 15th, 2020 12:52 AM

Roche to Pay $775M to Blueprint Medicines for Rights to Pralsetinib for RET-Altered Tumors

"... cell lung cancer, medullary thyroid cancer, as well as other solid tumors. ... for pralsetinib in RET-mutant and RET fusion-positive thyroid cancers."

Published: Jul 15th, 2020 12:48 AM

Noteworthy Tuesday Option Activity: INTU, CTXS, HON

"Pralsetinib, proposed for the treatment of RET fusion-positive NSCLC, RET mutation-positive MTC, and RET fusion-positive thyroid cancer, is under FDA ..."

Published: Jul 14th, 2020 9:18 PM

Should Value Investors Buy Asbury Automotive Group (ABG) Stock?

"Separately, 60% of previously treated and 74% of treatment naive RET-mutant medullary thyroid cancer patients responded to pralsetinib. Roche's ..."

Published: Jul 14th, 2020 8:26 PM

Elmont continues to face high cancer rates

"In one case, Mimi Pierre-Johnson said, a man who had lived in Elmont for more than 40 years was diagnosed with medullary thyroid cancer, despite ..."

Published: Jul 14th, 2020 8:00 PM

Roche pits its targeted cancer Blueprint against Lilly

"Lilly's own Ret inhibitor Retevmo (selpercatinib) was recently approved in Ret-mutated non-small cell lung and thyroid cancers, giving it a few months' ..."

Published: Jul 14th, 2020 7:23 PM

Roche pays $775M upfront for Cambridge biotech's sophomore cancer drug

"The medication, known as pralsetinib or BLU-667, is designed for cancers linked to the RET gene. That includes non-small cell lung cancer and ..."

Published: Jul 14th, 2020 7:01 PM

Could A $775 Million Roche-Blueprint Deal Unseat Eli Lilly In Cancer?

"Retevmo was the first cancer treatment to target RET and gain FDA approval. Blueprint and Roche hope to follow. The biotech company has already ..."

Published: Jul 14th, 2020 5:06 PM

Roche collaborates with Blueprint Medicines for new treatment of RET-altered cancers

"Blueprint Medicines has submitted a new drug application (NDA) for pralsetinib to the US Food and Drug Administration (FDA) and a marketing ..."

Published: Jul 14th, 2020 3:52 PM

Roche to pay Blueprint $775M for pralsetinib rights, setting up showdown with Lilly

"Lilly won FDA approval for Retevmo in the treatment of NSCLC and two types of thyroid cancer in May. Blueprint is targeting the same indications and ..."

Published: Jul 14th, 2020 3:09 PM

Diagnostic champ Roche buys its way into the RET title fight with Eli Lilly, paying $775M in cash to ...

"Four years later, pralsetinib is on the cusp of potential approval and the Swiss pharma giant is putting in much more to get in on the commercial game."

Published: Jul 14th, 2020 12:52 PM

Roche gene testing key to $1.7 billion deal for Blueprint cancer drug

"The Swiss drugmaker will pay $675 million in cash and make a $100 million equity investment in Blueprint for rights to pralsetinib, which could gain ..."

Published: Jul 14th, 2020 11:50 AM

Vienna Airport June passenger numbers down 95%

"Earlier this month, Blueprint also submitted pralsetinib to the FDA for treating advanced RET mutant and RET fusion-positive thyroid cancers. "In bringing ..."

Published: Jul 12th, 2020 5:00 PM

Vandetanib Remains Safe and Effective in Medullary Thyroid Cancer

"A post-hoc analysis of the phase III ZETA trial shows that vandetanib improved PFS in medullary thyroid cancer. The tyrosine kinase inhibitor vandetanib ..."

Published: Jul 10th, 2020 9:52 PM

Coronavirus: Kiwi diagnosed with rare cancer in Romania struggling to get home

"It revealed he had stage four medullary thyroid cancer. Nick Daniels has stage four thyroid cancer. He is trying to come home to Auckland. Nick Daniels/ ..."

Published: Jul 6th, 2020 11:20 AM

Parents of boy, 4, with rare cancer pin hopes on experimental drug

"... ONC201 trials had "shown minimal to no efficacy". However, "if the mother needs to feel that she has done everything, we will help her in her efforts."

Published: Jul 3rd, 2020 12:29 AM

NCI Trials for July 2020

"NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of LOXO-292 in Patients with Tumors Harboring RET ..."

Published: Jul 2nd, 2020 5:56 PM

FDA Approval Sought for Pralsetinib to Treat Advanced RET+ Thyroid Cancers

"... treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) and RET fusionpositive thyroid cancers, according to ..."

Published: Jul 2nd, 2020 10:22 AM

LMNL Joins COVID-19 Battle, PFE/BNTX Vaccine Data Promising, EVLO On Watch

"Pralsetinib is an investigational, once-daily precision therapy designed to potently and selectively inhibit RET fusions and mutations, including ..."

Published: Jul 2nd, 2020 3:17 AM

FDA Approval Sought for Pralsetinib in RET+ Medullary Thyroid Cancer

""Pralsetinib has broad potential to address the medical needs of patients with RET-altered cancers, who have not traditionally benefited from targeted ..."

Published: Jul 2nd, 2020 12:41 AM

Blueprint Medicines Files NDA for Pralsetinib for RET-Driven Thyroid Cancers

"The FDA granted accelerated approval to selpercatinib in May for patients with RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer, and ..."

Published: Jul 1st, 2020 6:18 PM

Estrogen Receptor Agent Approved

"Retevmo Approved in Lung and Thyroid Cancers. On May 8, the U.S. Food and Drug Administration (FDA) announced the approval of Retevmo ( ..."

Published: Jul 1st, 2020 5:00 PM

Blueprint Medicines Announces Submission of New Drug Application to FDA for Pralsetinib for the ...

"Pralsetinib is an investigational, once-daily precision therapy designed to potently and selectively inhibit RET fusions and mutations, including predicted ..."

Published: Jul 1st, 2020 2:56 AM

Progress in Targeted Therapy for Lung Cancer: New Data From ASCO 2020

"Please note that in the selpercatinib approval, it is available for any line of therapy and should be considered as a first therapy. Looking for RET is ..."

Published: Jun 30th, 2020 1:37 AM

OmniSeq Offers Differentiating Platform to Clinically Detect Rare Genetic Alterations to Identify ...

"... lung cancer, of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who ..."

Published: Jun 29th, 2020 6:41 PM

Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx for Pralsetinib in China

"Pralsetinib is an investigational treatment for the detection of RET alterations in cancer patients. Burning Rock Chief Medical Officer Hao Liu said in a ..."

Published: Jun 29th, 2020 6:09 AM

BRIEF-Burning Rock And CStone Pharmaceuticals Reached Strategic Collaboration On Co ...

"... Rock And CStone Pharmaceuticals Reached Strategic Collaboration On Co-Development Of Companion Diagnostics For Pralsetinib In China."

Published: Jun 26th, 2020 7:07 PM

Pulmonary abnormalities, lung cysts seen in children, young adults with MEN2B

""This study evaluated lung function and anatomy in patients with MEN2B using pulmonary function tests and available CT images," Jaydira Del Rivero, ..."

Published: Jun 24th, 2020 10:15 AM

Dr. Halmos on Recent Advancements in NonSmall Cell Lung Cancer

"Another advance is the development and the awaited approval of pralsetinib (BLU-667). These agents are exceptional treatment options for patients ..."

Published: Jun 22nd, 2020 6:05 PM

NCCN Updates Clinical Practice Guideline for Thyroid Carcinomas

"After FNA results yield a medullary thyroid carcinoma diagnosis, a new bullet is listed under diagnostic procedures for additional cross-sectional ..."

Published: Jun 20th, 2020 12:52 AM

VIDEO: Advantages of aggressive therapy for metastatic EGFR-mutated NSCLC

"Rotow also mentioned the recent FDA approval of selpercatinib for the treatment of RET fusion-positive NSCLC. She highlighted findings from a ..."

Published: Jun 19th, 2020 11:45 PM

Non-small-cell lung cancer therapies lead FDA approvals in May

"In addition to Tabrecta and Retevmo were Qinlock (ripretinib, Deciphera Pharmaceuticals Inc.), a kinase inhibitor, for advanced gastrointestinal ..."

Published: Jun 18th, 2020 6:30 PM

$400000 SBIR grant fast-tracks new approach to treating lung, thyroid cancers

"KinaRx portfolio includes therapeutic candidates for acute myeloid leukemia, lung cancer, and medullary thyroid cancer, among others. About Purdue ..."

Published: Jun 15th, 2020 8:56 PM

Selpercatinib shows durable response in RET-fusion positive NSCLC

""LOXO-292, or selpercatinib, is a highly potent selective RET-inhibitor," Vivek Subbiah, MD, associate professor at The University of Texas MD Anderson ..."

Published: Jun 15th, 2020 5:00 PM

Increasing incidence of cancer and stage migration towards advanced disease in children and ...

"... whereas stage migration towards advanced disease was seen for Hodgkin lymphomas, soft tissue sarcomas and medullary thyroid carcinomas."

Published: Jun 12th, 2020 5:55 PM

Nurses Unlock Role in Cancer Genetics

"People found to have a genetic mutation for medullary thyroid cancer can encourage family members to undergo screening, as there is a nearly 100% ..."

Published: Jun 11th, 2020 7:03 PM

Pralsetinib Appears Promising in RET Fusion-Positive NSCLC

"Pralsetinib, an oral selective RETkinase inhibitor, targets both RET fusions and alterations. For the ARROW study (ClinicalTrials.gov identifier: ..."

Published: Jun 11th, 2020 3:18 AM

Genetic Testing Becomes Vital in Sequencing Treatments for Patients With Thyroid Cancer

"The highly selective RET inhibitor pralsetinib (BLU-667), for example, is under investigation now and has shown encouraging findings in thyroid ..."

Published: Jun 9th, 2020 9:18 PM

NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program

"... for metastatic medullary thyroid cancer patients, or the NGS Thyroid Profile plus RET FISH test for non-metastatic medullary thyroid cancer patients."

Published: Jun 9th, 2020 3:41 PM

First patient dose delivered for Lilly's tirzepatide cardiovascular outcomes trial

"Trulicity may cause tumors in the thyroid, including thyroid cancer. ... have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC)."

Published: Jun 8th, 2020 11:56 PM

Real Housewife Alum Jill Zarin on Finding Love After Cancer Loss: Says Husband Would Approve ...

"Medullary thyroid cancer accounts for approximately 2% of all thyroid cancers. Approximately 25% of all medullary thyroid cancer is inherited, and a test ..."

Published: Jun 7th, 2020 6:07 PM

Fundraising vital as family of Eva Williams wait to see if she will be accepted on to one of four ...

"... all essentially means is that the trials aren't readily accessible and we feel as though time is probably running out on us accessing the ONC201 trial."

Published: Jun 7th, 2020 1:48 PM

Selpercatinib Prompts Dramatic Response in RET Fusion-Positive Ansplastic Thyroid Carcinoma

"... RET-mutant medullary thyroid cancer and those with other RET fusion-positive thyroid cancers in the phase I/II LIBRETTO-001 trial (NCT03157128), ..."

Published: Jun 6th, 2020 4:03 AM

"Mommy, my brain hurts," a kindergartner tells her mother. The girl is then diagnosed with a brain ...

"ONC201, an experimental drug, is part of a Phase I testing study at the hospital, Raegen Sieck said. "We are going to put all of our hope and faith into ..."

Published: Jun 5th, 2020 8:22 PM

Blueprint Medicines (BPMC) Up 15.5% Since Last Earnings Report: Can It Continue?

"Additionally, pralsetinib is being studied for the treatment of RET-mutant medullary thyroid carcinoma (MTC). The company is further on track to file an ..."

Published: Jun 5th, 2020 6:18 PM

RET Inhibition Shows Significant Intracranial Responses in RET-Altered NSCLC

""Selpercatinib had marked intracranial anti-tumor activity in RET fusionpositive patients with [NSCLC and] CNS metastases. Tumor responses were ..."

Published: Jun 4th, 2020 9:18 AM

Exelixis (EXEL) Down 11.5% Since Last Earnings Report: Can It Rebound?

"... of medullary thyroid cancer generated $4.7 million in net product revenues. ... Tecentriq in patients with locally advanced or metastatic solid tumors."

Published: Jun 3rd, 2020 8:00 PM

Asco 2020 movers cell therapy companies dominate the risers

"Supportive sellside analysts duly described TPX-0046 as potentially best-in-class, no doubt mindful of the $325m offering that Turning Point had ..."

Published: Jun 3rd, 2020 8:56 AM

$2 million SBIR grant fast-tracks cancer drug platform technology

"KinaRx portfolio includes therapeutic candidates for acute myeloid leukemia, lung cancer, medullary thyroid cancer, among others. About Purdue ..."

Published: Jun 2nd, 2020 11:56 PM

Blueprint's Positive Pralsetinib Data Places New Option on Horizon for RET-Altered Cancer Patients

"... medullary thyroid cancer, and RET fusion-positive thyroid cancer. ... In this 27-patient cohort, 13 patients had RET fusion-positive thyroid cancer, and ..."

Published: Jun 2nd, 2020 7:38 PM

US FDA approval tracker: several early decisions in May

"Retevmo, which Lilly gained through its Loxo acquisition, was approved in ... Retevmo (selpercatinib), Eli Lilly, 1,172, Approved (early ~2 months)."

Published: Jun 2nd, 2020 2:22 AM

A Look Back at the FDA News from May 2020

"Pralsetinib (BLU-667) was granted a priority review on May 29, 2020, for the treatment of patients with advanced solid tumors harboring RET ..."

Published: Jun 1st, 2020 8:00 PM

Pralsetinib Active Across RET+ Tumor Types and Gains FDA Review

"RET inhibitor pralsetinib (BLU-667) induced responses in a number of patients with rare and difficult to treat RET fusionpositive solid tumors."

Published: Jun 1st, 2020 5:56 PM

Turning Point Therapeutics to Participate in Goldman Sachs 41st Annual Global Healthcare ...

"... TPX-0046, targeting RET and SRC, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic ..."

Published: Jun 1st, 2020 5:45 AM

Pralsetinib Demonstrates Significant Findings in RET+ Solid Tumors as FDA Grants Priority Review

"In thyroid cancers specifically, RET fusions can be found in about 10% to 20% of papillary thyroid cancers (PTCs), mutations are found in about 50% of ..."

Published: May 31st, 2020 8:00 PM

Blueprint gets FDA priority review for competitor to newly approved Lilly cancer drug

"... medullary thyroid cancer. Blueprint said it plans to file for FDA approval of pralsetinib in RET mutant- and fusion-positive thyroid cancers next month."

Published: May 31st, 2020 10:15 AM

Jefferson, Chad

"... son of Charles and Connie Jefferson, passed away from complications of a brain injury during his battle with Medullary Thyroid Cancer, while being ..."

Published: May 31st, 2020 5:18 AM

ASCO 2020: Targeted therapy pralsetinib achieves high response rates in advanced cancers with ...

"The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumours harbouring RET ..."

Published: May 31st, 2020 2:45 AM

ASCO 2020: Oncoceutics' ONC201 Demonstrates Clinical Benefit

"To date, tumors with an H3 K27M mutation have no effective treatments. They are also associated with poor overall survival. ONC201, a "founding ..."

Published: May 30th, 2020 3:51 AM

Other news to note for May 29, 2020

"TPX-0046 also demonstrated antitumor activity in RET-driven cell-derived and patient-derived xenograft tumor models, including those that harbor a ..."

Published: May 29th, 2020 7:15 PM

Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene ...

"RET alterations are most common in medullary thyroid cancers (approximately 90% of advanced cases), papillary thyroid cancers (approximately ..."

Published: May 29th, 2020 5:33 PM

BRIEF-Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate

"TURNING POINT THERAPEUTICS INC - A PHASE 1/2 TRIAL OF TPX-0046 IN RET TKI-NAVE AND -PRETREATED PATIENTS IS ONGOING Source ..."

Published: May 29th, 2020 5:00 PM

BRIEF-Blueprint Medicines Highlights Durable Clinical Activity And Well-Tolerated Safety Profile Of ...

"* BLUEPRINT MEDICINES CORP - NDA ACCEPTED BY FDA AND MAA VALIDATED BY EMA FOR PRALSETINIB IN RET FUSION-POSITIVE NSCLC ..."

Published: May 28th, 2020 2:37 AM

Pulmonary function in patients with multiple endocrine neoplasia 2B (MEN2B)

"They included 36 patients with MEN2B (18 males, 18 females) based on the availability of PFTs; 27 patients had undergone at least two PFTs and ..."

Published: May 27th, 2020 5:56 PM

Pulmonary and thyroid carcinoma: FDA approves the treatment with Retevmo

"The Food and Drug Administration (FDA) approved Retevmo (selpercatinib) for three types of cancer treatment that present alteration (changing) in the ..."

Published: May 26th, 2020 5:00 PM

Blueprint Medicines to Host Conference Call to Review Updated Clinical Data for Pralsetinib in ...

"ET on Friday, May 29, 2020 to review updated clinical data for pralsetinib in RET-altered cancers. The data will also be presented in the American ..."

Published: May 20th, 2020 2:00 AM

8 recent drug approvals

"The FDA approved Retevmo, Eli Lilly's drug designed to treat three types of tumors non-small cell lung cancer, medullary thyroid cancer and other ..."

Published: May 19th, 2020 7:37 PM

Multiple Treatment Guideline Updates Released for Lung Cancer

"Selpercatinib was added as a "preferred" first-line and subsequent treatment option (category 2A), cabozantinib and vandetanib were added as ..."

Published: May 19th, 2020 5:45 AM

Turning Point Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock

"... trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET and SRC, which is currently ..."

Published: May 16th, 2020 12:52 AM

Onc Daily: Olaparib in Ovarian Cancer, Smoking and Lung Cancer Survival

"Update on Medullary Thyroid Carcinoma. The Medscape reference team has updated the detailed information on medullary thyroid carcinoma to include ..."

Published: May 15th, 2020 8:33 PM

Blueprint's Ayvakit gets FDA no-go in new stomach cancer use but presses ahead in blood disorder

"In a phase 2 trial, pralsetinib triggered a response in 65% of patients with RET fusion-positive NSCLC, according to updated data set for presentation ..."

Published: May 15th, 2020 7:03 PM

Selpercatinib receives FDA nod

"The presence of RET alterations must be confirmed via laboratory testing before initiating treatment with selpercatinib. Advertisement. The approval is ..."

Published: May 15th, 2020 2:45 AM

Retevmo Approved for RET-Driven NSCLC and Thyroid Cancers

"adults and children at least 12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; ..."

Published: May 15th, 2020 1:37 AM

With new lung cancer data at ASCO, Blueprint Medicines nips at Eli Lilly's heels

"The company will present a poster on pralsetinib, its RET inhibitor, which some analysts wrote they view as being "interchangeable" with Lilly's Retevmo, ..."

Published: May 14th, 2020 6:41 PM

FDA approves Retevmo, first therapy for lung and thyroid cancers with RET gene alterations

"FDA has approved Retevmo (selpercatinib) capsules to treat non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers in ..."

Published: May 14th, 2020 5:56 PM

Blueprint Medicines Announces Data Presentations Highlighting Significant Progress in Advancing ...

"Oral Presentation. Presentation Title: Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. Session Title: ..."

Published: May 14th, 2020 3:07 PM

FDA Approves RET Inhibitor Retevmo for Lung and Thyroid Cancer

"Medullary thyroid cancer, which involves a specific type of cell, is uncommon-accounting for only 4% of all thyroid cancers-but it frequently has RET ..."

Published: May 14th, 2020 3:07 AM

Biotech ETFs to Gain From Latest Advancements in Cancer Drugs

"... cell lung cancer, medullary thyroid cancer and other types of thyroid cancers in patients whose tumors have an alteration (mutation or fusion) in a ..."

Published: May 14th, 2020 2:33 AM

Lilly Cancer Treatment Lands FDA Approval

"... cancer, as well as the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid ..."

Published: May 14th, 2020 2:05 AM

Days after rapid FDA approval, Lilly and Blueprint go head-to-head again at ASCO

"Lilly got an edge with an FDA approval for its drug, called selpercatinib or Retevmo, last week - months ahead of the agency deadline - but ..."

Published: May 14th, 2020 2:03 AM

ASCO: Blueprint's RET inhibitor pads its case ahead of FDA lung cancer decision

"Pralsetinib, also called BLU-667, shrank tumors in 100% of those patients. Nearly three-quarters of them had enough shrinkage to be responders."

Published: May 14th, 2020 2:00 AM

ASCO: Blueprint's RET inhibitor pads its case ahead of FDA lung cancer decision

"Blueprint submitted pralsetinib for FDA approval as a treatment for RET fusion-positive NSCLC in the first quarter this year, and with a priority review ..."

Published: May 13th, 2020 11:11 PM

The Role of Multikinase TKIs for NSCLC

"Shirish M. Gadgeel, MD, MBBS: The efficacy results with multikinase tyrosine kinase inhibitors are better in patients with medullary thyroid carcinoma ..."

Published: May 12th, 2020 3:07 PM

Lilly's Retevmo wins US nod for specific lung, thyroid cancers

"US regulators have approved Eli Lilly's Retevmo (selpercatinib) as the first therapeutic specifically designed for patients with advanced RET-driven ..."

Published: May 12th, 2020 3:11 AM

Retevmo (selpercatinib) FDA Approval History

"Retevmo (selpercatinib) is a kinase inhibitor for the treatment of patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC), ..."

Published: May 12th, 2020 1:15 AM

Under Armour, Marriott fall; Cardinal Health, AMC rise

"The pharmaceutical company's cancer drug Retevmo was approved by the Food and Drug Administration. Quidel Corp., up $50.35 to $208.95."

Published: May 12th, 2020 12:18 AM

Blueprint Medicines up 11% on prospects of RET inhibitor pralsetinib

"Blueprint Medicines (BPMC +10.7%) is poised for its best one-day gain in a month on the heels of a note from SVB Leerink on RET inhibitor pralsetinib ..."

Published: May 11th, 2020 11:56 PM

Onc Daily: Selpercatinib Approved, ASCO Goes Virtual

"... of RET-positive tumors in adults with nonsmall cell lung cancer that has spread; the treatment of advanced medullary thyroid cancer (MTC) or MTC ..."

Published: May 11th, 2020 9:41 PM

Recon: FDA approves Lilly's Retevmo for thyroid, lung cancers; China approves Novartis' MS drug ...

"Recon: FDA approves Lilly's Retevmo for thyroid, lung cancers; China approves Novartis' MS drug Mayzent. Posted 11 May 2020 | By Michael Mezher."

Published: May 11th, 2020 8:56 PM

FDA Approves Selpercatinib for Certain NonSmall Cell Lung, Thyroid Cancers

"Selpercatinib is a kinase inhibitor which helps to prevent cancer cells from growing. Prior to beginning treatment, an RET gene mutation must be ..."

Published: May 11th, 2020 8:33 PM

Opdivo-Yervoy Combination Continues to Show Superior Long-Term Outcomes in Renal Cell ...

""The ORRs in patients with intermediate- and poor-risk disease who received ... NSCLC that has spread in adults; Advanced medullary thyroid cancer ..."

Published: May 11th, 2020 8:22 PM

Lilly cashes in on Loxo buyout with FDA approval for first-in-class cancer drug Retevmo

"Blueprint's RET inhibitor pralsetinib, also known as BLU-667, hit a 61% response rate in RET fusion-positive NSCLC patients. The company recently ..."

Published: May 11th, 2020 5:11 PM

FDA approves Retevmo for lung cancer, thyroid cancer subsets

"... RET fusion-positive non-small cell lung cancer that has spread; advanced RET fusion-positive medullary thyroid cancer or medullary thyroid cancer ..."

Published: May 11th, 2020 4:06 PM

Drugmakers Overhaul the Sales Pitch Amid Coronavirus Lockdowns

"The new Lilly drug, Retevmo, treats lung and thyroid cancers that have certain genetic traits. After many employees began working from home in ..."

Published: May 11th, 2020 2:56 PM

FDA clears Lilly's Retevmo for RET-positive lung, thyroid cancers

"Retevmo reaches the market after Loxo's Vitrakvi (larotrectinib), which was approved by the FDA to treat any solid tumour that has a neurotrophic ..."

Published: May 10th, 2020 10:00 PM

UPDATED: A groundbreaking cancer drug nabs fast OK, giving Eli Lilly boasting rights as a rival ...

"Regulators stamped their OK on selpercatinib, which can now be marketed as Retevmo to patients suffering from 3 different types of cancers all driven ..."

Published: May 10th, 2020 9:52 PM

A groundbreaking cancer drug nabs fast OK, giving Eli Lilly boasting rights as a rival speeds close ...

"The FDA action covers RET fusion-positive non-small cell lung cancer and thyroid cancer, along with RET-mutant medullary thyroid cancer."

Published: May 10th, 2020 4:37 PM

Lilly Receives US FDA Approval for Retevmo (selpercatinib), the First Therapy Specifically for ...

""The approval of selpercatinib marks an important milestone in the treatment of NSCLC, making RET-driven cancers now specifically targetable in the ..."

Published: May 10th, 2020 12:19 AM

Lilly's Loxo buyout bears fruit as FDA clears cancer drug Retevmo

"Retevmo is the eighth cancer drug approved by the FDA this year, following new medicines for breast, lung, liver and gastrointestinal cancers. Later this ..."

Published: May 9th, 2020 6:12 PM

Eli Lilly Receives US FDA Approval For Retevmo

"Retevmo is Expected to Be Available From Specialty Pharmacies Within One Week."

Published: May 9th, 2020 12:30 PM

Retevmo (selpercatinib) FDA Approval History

"FDA approval history for Retevmo (selpercatinib) used to treat Non-Small Cell Lung Cancer, Thyroid Cancer. Supplied by Eli Lilly and Company."

Published: May 9th, 2020 7:08 AM

BRIEF-Eli Lilly Receives US FDA Approval For Retevmo

"* RETEVMO IS EXPECTED TO BE AVAILABLE FROM SPECIALTY PHARMACIES WITHIN ONE WEEK. Source text for Eikon: Further company ..."

Published: May 9th, 2020 5:33 AM

Lilly Receives US FDA Approval for Retevmo(TM) (selpercatinib), the First Therapy Specifically for ...

"Retevmo may affect both tumor cells and healthy cells, which can result in side effects. Retevmo is an oral prescription medicine, 120 mg or 160 mg ..."

Published: May 9th, 2020 5:22 AM

Lilly Receives US FDA Approval for Retevmo (selpercatinib), the First Therapy Specifically for ...

"... for Patients with Advanced RET-Driven Lung and Thyroid Cancers ... RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, ..."

Published: May 9th, 2020 4:15 AM

Lilly Moves Ahead With Retevmo Launch In A Challenging Environment

"The company secured FDA approval for selpercatinib in RET-driven NSCLC and thyroid cancer, months ahead of the PDUFA date. Oncology ..."

Published: May 9th, 2020 3:52 AM

FDA Approves Selpercatinib for RET-Mutant NSCLC, Thyroid Cancers

"Advanced or metastatic medullary thyroid cancer in patients aged 12 or older who require systemic therapy; Advanced RET fusion-positive thyroid ..."

Published: May 9th, 2020 2:45 AM

FDA Approves First Therapy for Patients with Lung and Thyroid Cancers with a Certain Genetic ...

"Retevmo is the first therapy approved specifically for cancer patients with the RET gene alterations. "Innovations in gene-specific therapies continue to ..."

Published: May 8th, 2020 5:45 PM

'Consistent increase' observed in larger, more aggressive thyroid tumors in California

""Papillary, medullary and anaplastic histological subtypes showed increasing incidence rates, while the incidence of follicular carcinoma remained ..."

Published: May 8th, 2020 12:18 PM

Hopes high that Eva Williams will start lifeline treatment in eight weeks as she approaches 10th ...

""We spoke today with our oncologist at Alder Hey and he again re-enforced that the ONC201 trial is something to pursue, however we also discussed ..."

Published: May 7th, 2020 10:38 PM

Blueprint Medicines (BPMC) Q1 Earnings Top, Revenues Soar Y/Y

"Additionally, pralsetinib is being studied for the treatment of RET-mutant medullary thyroid carcinoma (MTC). The company is further on track to file an ..."

Published: May 6th, 2020 8:56 PM

Exelixis (EXEL) Q1 Earnings and Revenues Surpass Estimates

"... of medullary thyroid cancer generated $4.7 million in net product revenues. ... Tecentriq in patients with locally advanced or metastatic solid tumors."

Published: May 6th, 2020 3:52 PM

Blueprint Medicines Reports First Quarter 2020 Financial Results

"Submitted US and EU marketing applications for pralsetinib for RET fusion-positive NSCLC; On track to submit NDA to FDA for pralsetinib for ..."

Published: May 5th, 2020 7:48 PM

First ever case report of co-occurrence of hobnail variant of papillary thyroid carcinoma and ...

"Likewise, primary hyperparathyroidism with such non-medullary thyroid carcinoma is rare. The specific molecular profile of hobnail PTC (HPTC) is ..."

Published: May 4th, 2020 8:22 PM

Consensus on Thyroid Fine Needle Aspiration Biopsies During the COVID-19 Pandemic

"Conversely, as delays in diagnosis and treatment for medullary thyroid cancer can adversely affect the prognosis, it is recommended to assess ..."

Published: May 4th, 2020 6:03 PM

Turning Point Therapeutics to Host First Quarter Conference Call

"... patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET and SRC, which is currently being ..."

Published: May 2nd, 2020 11:22 PM

Martha Bowen

"... away peacefully in her home, surrounded by her beloved family on April 30, 2020, after a 10-year courageous battle with medullary thyroid cancer."

Published: May 2nd, 2020 1:59 PM

Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in ...

"Selpercatinib and pralsetinib are potent and selective tyrosine kinase inhibitors targeting the rearranged during transfection (RET) receptor in various ..."

Published: Apr 30th, 2020 2:56 PM

Medicare rebate for rare cancer diagnosis test

""I was diagnosed 29 years ago with medullary thyroid cancer and there was no treatment for me for 28 years and my cancer progressed," she said. Last ..."

Published: Apr 30th, 2020 12:30 PM

Familial aggregation and heritability of non-medullary thyroid cancer in an Asia population: A ...

"In this nationwide cohort study, researchers evaluated the extent of familial aggregation of non-medullary thyroid cancer (NMTC) and the relative risks ..."

Published: Apr 27th, 2020 8:33 PM

COVID-19: Defer 'Bread and Butter' Procedure for Thyroid Nodules

"Exceptions for considering FNA include more urgent thyroid disease ... "Regarding medullary thyroid cancer (MTC), early diagnosis and surgery do ..."

Published: Apr 24th, 2020 11:33 AM

Bone metastases in medullary thyroid carcinoma: high morbidity and poor prognosis associated ...

"In this retrospective cohort study involving 1,060 medullary thyroid carcinoma (MTC) patients, researchers described the prevalence of bone ..."

Published: Apr 21st, 2020 8:00 PM

The Role of RET Rearrangements in Lung Cancer

"... which is formerly known as BLU-667, and selpercatinib, formerly known as LOXO-292. We entered with it being investigated in patients specifically ..."

Published: Apr 17th, 2020 5:56 PM

Most fine-needle aspiration thyroid biopsies can be 'safely delayed' during COVID-19

"Patients with suspected medullary thyroid cancer (MTC), which is relatively rare, should undergo measurement of serum calcitonin and be referred ..."

Published: Apr 10th, 2020 8:45 PM

Study Describes First Mechanism of Resistance to RET Inhibitor Selpercatinib

"... against tumors, such as non-small cell lung cancer (NSCLC) or medullary thyroid cancer (MTC), that are positive for RET fusions or mutations."

Published: Apr 10th, 2020 5:22 PM

Cancer biotech Oncoceutics loses CEO, chair and co-founder

"The first lead compound to emerge from this program is ONC201, an orally active small-molecule DRD2 antagonist. The company is supported by ..."

Published: Apr 9th, 2020 2:33 AM

Philadelphia biopharma firm shakes up its leadership

"Its lead compound, ONC201, is in early stage testing initially as a potential treatment for glioma, an aggressive subtype of brain cancer. In addition to ..."

Published: Apr 4th, 2020 2:56 AM

Dr. Levy on Emerging Biomarkers and Corresponding Therapies in Lung Cancer

"For RET fusions, selpercatinib (LOXO-292) has shown an objective response rate (ORR) upward of 85%, adds Levy. Additionally, AMG 510 is an oral ..."

Published: Apr 2nd, 2020 8:00 PM

Rolling NDA Submitted for Pralsetinib in RET+ NSCLC Based on Topline ARROW Data

"Topline data were reported for patients with RET-mutant medullary thyroid cancer (MTC), both untreated patients and those who had previously ..."

Published: Apr 1st, 2020 8:33 PM

Blueprint Medicines Advance Pralsetinib in Multiple RET-Mutant Indications

"... RET-based oncology drug programs, including top-line data from the pralsetinib trial for patients with RET-mutant medullary thyroid cancer (MTC)."

Published: Apr 1st, 2020 5:45 PM

Blueprint Medicines' pralsetinib shows positive action in RET-altered thyroid cancer

"... announces a pipeline update including topline data from the Phase 1/2 ARROW study evaluating pralsetinib (BLU-667) in patients with solid tumors."

Published: Apr 1st, 2020 5:03 PM

Blueprint Medicines Announces the Achievement of Key Portfolio Milestones

"74% overall response rate in treatment-naive RET-mutant medullary thyroid cancer and 89% overall response rate in RET fusion-positive thyroid ..."

Published: Mar 30th, 2020 8:22 PM

Trends in Thyroid Cancer Incidence and Incidence-Based Mortality in California

"The most common histologic type was papillary thyroid carcinoma (87.8%) followed by follicular thyroid carcinoma (7.2%) and medullary thyroid ..."

Published: Mar 30th, 2020 6:00 PM

2020 Market Spotlight: Thyroid Cancer - ResearchAndMarkets.com

"Selpercatinib for Thyroid Cancer (September 29, 2019); Pralsetinib for ... Figure 7: Pralsetinib for Thyroid Cancer (June 3, 2019): Phase I/II - ARROW ..."

Published: Mar 28th, 2020 1:37 AM

UCLA, UT Southwestern join NCCN

"... he was vice president of Research and Development at Loxo Oncology, where he led the overall clinical development of selpercatinib (LOXO-292, ..."

Published: Mar 27th, 2020 5:00 PM

Thyroid Cancer Market Study, 2014-2026 - Novartis Leads Industry Sponsors With the Highest ...

"Figure 6: Selpercatinib for Thyroid Cancer (September 29, 2019): Phase I/II - LIBRETTO-001. Figure 7: Pralsetinib for Thyroid Cancer (June 3, 2019): ..."

Published: Mar 26th, 2020 9:14 PM

Why Is Exelixis (EXEL) Down 15.6% Since Last Earnings Report?

"... of medullary thyroid cancer, generated $13.8 million in net product revenues. ... inhibitor, in patients with locally advanced or metastatic solid tumors."

Published: Mar 24th, 2020 7:57 PM

Meet 'Gentle George' the boy from Bishop's Stortford asking for help to get back to school

"MEN2B is a condition which creates tumours in three areas of the body, due to overactive endocrine glands. George's diagnosis came too late to ..."

Published: Mar 22nd, 2020 4:37 PM

Amazon Boosts Overtime Pay For US Warehouse Workers

"Cometriq treats medullary thyroid cancer. Are cancer ... Vertex essentially owns the market for treating rare genetic disease cystic fibrosis (CF)."

Published: Mar 21st, 2020 9:07 AM

Four regimens receive priority review for lung cancer indications

"The agent also received priority review for RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer. The FDA granted priority ..."

Published: Mar 21st, 2020 12:07 AM

Blueprint Medicines Corporation: An Undervalued Company With Attractive Prospects

"... cell lung cancer) and RET-mutation-positive MTC (medullary thyroid cancer). ... Currently, there are no effective approved therapies for this disease."

Published: Mar 17th, 2020 8:00 PM

Resources In Medicine Are Continually Targeted at Controlling COVID-19 Spread

"... Eli Lilly and Company to assist in identifying patients with non-small cell lung cancer and medullary thyroid cancer harboring RET variants who may ..."

Published: Mar 12th, 2020 8:00 PM

Thermo Fisher, J&J partner on next-generation sequencing diagnostic for cancer clinical trials

"... also known as LOXO-292. In that case, the test is being developed to look for RET fusions, which are the molecular target of selpercatinib, including ..."

Published: Mar 11th, 2020 3:30 AM

Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at Barclays Global Healthcare Conference ...

"And then we have a capsule formulation called COMETRIQ that is indicated for a rare form of thyroid cancer called medullary thyroid cancer. So, we're ..."

Published: Mar 10th, 2020 4:03 PM

Prediction of biochemical cure in patients with medullary thyroid cancer

"... biochemical cure in medullary thyroid cancer (MTC). Using multivariable logistic regression analysis, they determined clinical and histopathological ..."

Published: Mar 6th, 2020 11:45 PM

NCI Trials for March 2020

"A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)."

Published: Mar 6th, 2020 9:30 PM

American Association of Endocrine Surgeons Publishes Guidelines for Thyroid Disease Surgery

"All patients diagnosed with medullary thyroid carcinoma should undergo genetic testing for a germline RET mutation, and those with multiple ..."

Published: Mar 6th, 2020 5:00 PM

Morphology of bone metastases should guide treatment in medullary thyroid cancer

""The impact of bone metastases in metastatic medullary thyroid carcinoma (MTC) on patient morbidity and prognosis has not been studied in detail ..."

Published: Mar 4th, 2020 10:03 PM

Prognostic Effect of Bone Metastases in Medullary Thyroid Cancer

"Bone metastases are present in more than a quarter of patients with metastatic medullary thyroid carcinoma (MTC), most often with an osteolytic ..."

Published: Mar 4th, 2020 4:48 PM

Thyroid Cancer Drugs Market Forecasts, 2020-2030 - Increasing Use of Combination Drugs Spurs ...

"For example, Vandetanib (Caprelsa) and Cabozantinib (Cometriq) are targeted therapies used to treat advanced medullary thyroid cancer (MTC)."

Published: Feb 29th, 2020 5:56 PM

Boy with a fatal form of brain cancer to pursue trial in USA

"In a desperate bid to find options, Ms Hatzl has also considered a drug called ONC201, which has been shown to kill tumour cells in studies overseas, ..."

Published: Feb 29th, 2020 2:33 AM

George Labonte is running to show other survivors that cancer can't stop them

"In early 2016, I was diagnosed with a rare and incurable cancer called Medullary Thyroid Carcinoma. At the time, I wasn't sure if I would live out the ..."

Published: Feb 27th, 2020 11:11 PM

Exelixis: Potential Catalysts Ahead For This Mid-Cap Oncology Company

"Another drug, Cometriq capsules, has been approved by the FDA in progressive and metastatic medullary thyroid cancer indication. The active ..."

Published: Feb 26th, 2020 8:41 PM

Exelixis (EXEL) Beats on Earnings, Misses on Sales in Q4

"Cometriq (cabozantinib capsules), for the treatment of medullary thyroid cancer, generated $13.8 million in net product revenues. Exelixis also earned ..."

Published: Feb 26th, 2020 2:00 AM

Exelixis Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal Trial of ...

""Given the encouraging clinical activity observed for cabozantinib in phase 1 and 2 trials in differentiated thyroid cancer, and the poor prognosis for ..."

Published: Feb 24th, 2020 8:56 PM

Repurposing Astellas' and Novartis' leukemia drugs in resistant lung cancer

"Blueprint Medicines is studying a combination of Tagrisso with its RET inhibitor BLU-667 in patients with advanced EGFR-mutant NSCLC who also ..."

Published: Feb 24th, 2020 7:03 PM

Predictive Markers for mCRC

"We know there is the BLU-667 compound and there's a LOXO-292 compound that's currently out there being used for thyroid and lung cancer. And the ..."

Published: Feb 22nd, 2020 5:45 AM

Trulicity (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce ...

"Trulicity may cause tumors in the thyroid, including thyroid cancer. ... have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC)."

Published: Feb 20th, 2020 7:07 PM

Turning Point Therapeutics Names Siegfried Reich as Executive Vice President and Chief ...

"The company's pipeline of drug candidates also includes TPX-0022, ... or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, ..."

Published: Feb 19th, 2020 5:00 PM

Tmunity to Present at Upcoming Investor Conferences

"PHILADELPHIA--(BUSINESS WIRE)-- Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving ..."

Published: Feb 14th, 2020 9:25 PM

Blueprint Medicines (BPMC) Q4 Loss Narrows, Revenues Top Mark

"Blueprint Medicines initiated the rolling submission of NDA to the FDA for its precision therapy pralsetinib to address the RET fusion-positive ..."

Published: Feb 14th, 2020 1:03 AM

Blueprint Medicines Corporation's (BPMC) CEO Jeff Albers on Q4 2019 Results - Earnings Call ...

"This morning in addition to financial results for 2019, we will highlight key value drivers for Blueprint Medicines in 2020, discuss topline pralsetinib in ..."

Published: Feb 13th, 2020 7:15 PM

EU Speedy Review Success For Kite But Not For Lilly

"... therapy, will in the end be fast-tracked at the European Medicines Agency. Lilly failed to secure the speedy review it was seeking for selpercatinib ..."

Published: Feb 13th, 2020 5:00 PM

Blueprint Medicines Reports Fourth Quarter and Full Year 2019 Financial Results

"Announced top-line ARROW trial data for pralsetinib in RET fusion-positive NSCLC and initiated rolling NDA -. - Plan to present initial PIONEER trial ..."

Published: Feb 12th, 2020 9:41 PM

FDA Speeds Up Examination of 5 Drugs with Priority Review

"... RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer. With priority review, Eli Lilly is anticipating potential approval ..."

Published: Feb 12th, 2020 8:56 PM

Stock To Watch: Blueprint Medicines (BPMC)

"A New Drug Application for Pralsetinib for previously treated RET-mutant medullary thyroid cancer is expected to be filed with the FDA in the second ..."

Published: Feb 11th, 2020 4:48 PM

Interpace Biosciences Announces Another Pricing improvement for its Thyroid Assay

"... the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma. ThyraMIR is the first microRNA gene expression classifier."

Published: Feb 11th, 2020 4:03 PM

Exelixis bounces back with new prostate cancer data

"Exelixis bounces back with new prostate cancer data ... as a treatment for progressive, metastatic medullary thyroid cancer in the US and Europe."

Published: Feb 11th, 2020 1:48 AM

Testing for RET Fusions in NSCLC Remains Critical as Targeted Therapy BLU-667 Evolves

"The selective RET inhibitor BLU-667 has demonstrated durable responses in patients with RET fusion-positive lung cancer in the phase I ARROW ..."

Published: Feb 8th, 2020 7:03 PM

A Look Back at FDA News from January 2020

"... Review to Selpercatinib in RET Fusion+ NSCLC and Thyroid Cancer ... non-small cell lung cancer, RET-mutant medullary thyroid cancer, and RET ..."

Published: Feb 5th, 2020 1:48 AM

Jennifer Jeske, 47

"The family appreciates memorials to ThyCa Donation, Attn: Medullary Thyroid Cancer Research Fund, P.O. Box 1102, Olney, Maryland, 20830-1102."

Published: Feb 4th, 2020 8:00 PM

Investigators Seek New Standard in RET Fusion-Positive NSCLC

"Investigators hope selpercatinib (LOXO-292), a highly selective RET inhibitor, will demonstrate potential as a new standard of care (SOC) for patients ..."

Published: Feb 4th, 2020 7:48 PM

Takeda unveils profit surprise on Shire integration-and no US Natpara supply till 2021

"Takeda doesn't expect any Natpara sales in the U.S. into fiscal 2020 ending in March 2021, as discussions with FDA to resume supply after a recent ..."

Published: Jan 31st, 2020 11:00 PM

FDA Grants Priority Review to Selpercatinib for Lung and Thyroid Cancer Subsets

"The application is based on findings from the phase I/II LIBRETTO-001 trial, which evaluated selpercatinib in RET-altered NSCLC and thyroid cancers."

Published: Jan 30th, 2020 9:50 PM

Lilly's NDA for Selpercatinib Gets FDA's Priority Review

"... non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer ... Many industry players are adopting this method to bring new cancer ..."

Published: Jan 30th, 2020 9:41 PM

Lilly's NDA for Selpercatinib Gets FDA's Priority Review

"The company plans to complete the NDA submission for pralsetinib in the first quarter of 2020 to treat NSCLC while the same for the MTC indication is ..."

Published: Jan 30th, 2020 5:33 PM

Lilly keeps ahead of Blueprint with swift FDA review for selpercatinib

"... review for selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and thyroid cancer ..."

Published: Jan 30th, 2020 12:18 PM

Lilly's selpercatinib gets FDA priority review for lung and thyroid cancers

"Lilly's selpercatinib gets FDA priority review for lung and thyroid cancers ... fusion-positive thyroid cancer, and RET-mutant medullary thyroid cancer ..."

Published: Jan 30th, 2020 7:54 AM

CABA Hits New High, IMMP On Watch, SBPH Drops CATALYST

"... RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer has been granted priority review by the FDA - with a decision expected ..."

Published: Jan 29th, 2020 10:37 PM

FDA grants priority review to selpercatinib for RET-altered NSCLC, thyroid cancer

"The FDA granted priority review to selpercatinib for the treatment of advanced RET fusion-positive non-small cell lung cancer, RET-mutant medullary ..."

Published: Jan 29th, 2020 10:03 PM

FDA Grants Priority Review to Selpercatinib in RET Fusion+ NSCLC and Thyroid Cancer

"The New Drug Application (NDA) for selpercatinib (LOXO-292) was granted FDA Priority Review for the treatment of patients with advanced RET ..."

Published: Jan 29th, 2020 6:24 PM

Bay Street Likely To Open Higher

"Eli Lilly has applied for approval of the treatment in three different types of tumors with altered RET: non-small-cell lung cancer, medullary thyroid ..."

Published: Jan 29th, 2020 6:18 PM

Thyroid Cancer Symptom: A Lump On This Body Part Could Be An Early Warning Sign

"Thyroid Cancer Symptom: A Lump On This Body Part Could Be An Early Warning ... At its initial stages, thyroid cancer might not exhibit any symptoms. ... syndromes including Cowden's syndrome, familial medullary thyroid cancer, ..."

Published: Jan 29th, 2020 4:48 PM

Lilly's selpercatinib application nabs accelerated review in US

"... advanced RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer."

Published: Jan 29th, 2020 4:37 PM

Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application

"... RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer."

Published: Jan 28th, 2020 1:15 AM

National Brain Tumor Society Backs Oncoceutics' Phase II Trial for Subset of High-Grade Gliomas

"ONC201 is the first imipridone dopamine receptor D2 antagonist (DRD2) that treats high-grade glioma by selectively targeting G protein-coupled ..."

Published: Jan 24th, 2020 11:33 PM

Patients with Hypoparathyroidism Warned of Extended NATPARA Recall

"NATPARA was voluntarily pulled off the market by the manufacturer (Takeda) after small particles of rubber were found in some samples of the ..."

Published: Jan 24th, 2020 9:52 AM

Trial drug ONC201 hopes for wife of Boro coach Graeme Lee

"FOOTBALL fans in the North-East are being urged to show their support for the wife of a former player. Graeme Lee started his career with Hartlepool ..."

Published: Jan 24th, 2020 5:00 AM

CStone successfully hosted the first US R&D Day in New York

"A total of five NDA submissions in Mainland China and Taiwan for CS1001, an anti-PD-L1 monoclonal antibody; pralsetinib, a RET inhibitor; and ..."

Published: Jan 23rd, 2020 7:02 PM

Turning Point Therapeutics Names Garry Nicholson to Its Board of Directors

"The company's pipeline of drug candidates also includes TPX-0022, ... or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, ..."

Published: Jan 22nd, 2020 2:00 AM

Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock

"... to fund clinical trials for pralsetinib in RET-driven cancers, including its Phase 3 AcceleRET Lung clinical trial for pralsetinib in first-line RET-altered ..."

Published: Jan 20th, 2020 11:00 PM

Pralsetinib effective, safe for RET fusion-positive NSCLC

"Approximately 90% of patients with advanced medullary thyroid cancer have RET mutations. The ongoing phase 1/phase 2 ARROW trial evaluated ..."

Published: Jan 20th, 2020 4:03 PM

Lilly will aim for one $1bn-$5bn deal per quarter in 2020

"Another promising candidate Lilly gained from the Loxo takeover is LOXO-292, which is currently being studied in a phase 1/2 trial for non-small cell ..."

Published: Jan 17th, 2020 5:33 PM

Tmunity doses first patient in Phase 1 CART-TnMUC1 clinical trial

"Tmunity Therapeutics Inc., a clinical-stage biotherapeutics firm focused on advanced T-cell immunotherapy, has reportedly dosed the first patient in its ..."

Published: Jan 17th, 2020 4:15 AM

FDA approves Ozempic for cardiovascular risk reduction in adults with type 2 diabetes and ...

"It is not known if Ozempic will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people.Do not use ..."

Published: Jan 17th, 2020 3:52 AM

FDA approves Ozempic for cardiovascular risk reduction in adults with type 2 diabetes and ...

"It is not known if Ozempic will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Do not use ..."

Published: Jan 17th, 2020 12:07 AM

A venture firm warms to funding neuroscience

"But only three - the cell therapy companies Kyverna, Tmunity, and Arsenal Biosciences - are publicly known. Any hints? Unlock this article by ..."

Published: Jan 15th, 2020 5:00 PM

Tmunity Announces First Patient Dosed in Phase 1 Clinical Trial with CART-TnMUC1

"Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of ..."

Published: Jan 13th, 2020 6:52 PM

Turning Point Therapeutics Announces Program Updates and Milestones for 2020

"Multiple RET-Positive Patients with Solvent-Front Mutations Previously Treated with Other Investigational RET Inhibitors Dosed with TPX-0046"

Published: Jan 13th, 2020 5:56 PM

Blueprint Medicines Announces 2020 Corporate Goals

"Multiple marketing applications for avapritinib and pralsetinib currently under review or planned for submission in 2020, including 5 in the U.S. and 2 ..."

Published: Jan 12th, 2020 2:00 AM

Thyroid cancer is somewhat mysterious

"Thyroid cancer is one of the rarer cancers and not in the list of the top 10 ... The medullary thyroid cancer (MTC) comes from a different cell in the ..."

Published: Jan 11th, 2020 4:26 AM

GIST kissed ahead of V-Day PDUFA, Blueprint design plan for Ayvakit goes 'fourth'

"Blueprint also plans to submit, in the second quarter, an NDA to the FDA for pralsetinib for medullary thyroid cancer previously treated with an ..."

Published: Jan 11th, 2020 12:52 AM

Pralsetinib Achieves Durable Responses in Patients With RET+ NSCLC

"Pralsetinib (BLU-667), a highly-selected RET inhibitor, achieved a favorable overall response rate (ORR) with prolonged durability in patients with ..."

Published: Jan 10th, 2020 10:05 PM

Top-Line Data Reported for Pralsetinib in Patients with RET Fusion-Positive NSCLC

"... to the FDA for pralsetinib for the treatment of patients with medullary thyroid cancer (MTC) previously treated with an approved multikinase inhibitor."

Published: Jan 10th, 2020 2:56 AM

Turning Point Therapeutics Announces Management Transition

"The company's pipeline of drug candidates also includes TPX-0022, ... and TPX-0046, targeting RET and SRC, which is currently being studied in a ..."

Published: Jan 9th, 2020 7:37 PM

Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib

"Notably, pralsetinib is also being studied for RET-mutant medullary thyroid carcinoma (MTC). The company plans to complete the NDA submission for ..."

Published: Jan 9th, 2020 7:36 PM

Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib

"The ARROW study evaluated once-daily oral, pralsetinib in 80 patients with RET fusion-positive NSCLC who received prior treatment with ..."

Published: Jan 9th, 2020 4:15 PM

Thyroid Cancer Drug Market Had A Booming Decade || Celgene Corporation, AstraZeneca ...

"Global thyroid cancer drug market is rise gradually to an estimated value of ... thyroid cancer, Follicular thyroid cancer, Hurthle cell cancer, Medullary ..."

Published: Jan 9th, 2020 2:22 PM

Turning Point (TPTX) Marches Ahead, Awaits TRIDENT-1 Data Update In 2020

"Next up in the pipeline TPX-0046 is under phase I/II study for the treatment of advanced solid tumors with abnormal RET genes. Another clinical drug ..."

Published: Jan 9th, 2020 4:15 AM

Blueprint Reports High Response Rates From Lung Cancer Patients in Early Pralsetinib Trials

"In the second quarter, the company plans to file an NDA for the medullary thyroid cancer indication. RET fusions appear in approximately 1 to 2 ..."

Published: Jan 8th, 2020 10:15 PM

Lilly looms over Blueprint as the biotech files targeted cancer drug

"The biotech also intends to ask regulators to approve pralsetinib as a treatment for medullary thyroid cancer, with an application planned for the ..."

Published: Jan 8th, 2020 8:36 PM

Blueprint throws down targeted therapy gauntlet with new lung cancer data, FDA submission

"Its most advanced competitor is Indianapolis-based Eli Lilly's Loxo Oncology division, whose RET inhibitor LOXO-292 (selpercatinib) has also shown ..."

Published: Jan 8th, 2020 8:33 PM

Blueprint throws down targeted therapy gauntlet with new lung cancer data, FDA submission

"... Medicines said Wednesday that it had started a rolling submission to the Food and Drug Administration for the drug BLU-667 (pralsetinib), based on ..."

Published: Jan 8th, 2020 5:56 PM

Blueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission ...

"Blueprint Medicines also plans to submit an NDA to the FDA for pralsetinib for the treatment of patients with medullary thyroid cancer (MTC) previously ..."

Published: Jan 8th, 2020 12:37 AM

Orphan Drugs Market Growth Strategies by 2027 with Leading Key Players Takeda ...

"Based on disease the market is segmented into Hodgkin lymphoma, ... 1 (GD1), Metastatic medullary thyroid carcinoma, Advanced gastric cancer or ..."

Published: Jan 7th, 2020 7:03 PM

Thyroid nodules: diagnostic evaluation based on thyroid cancer risk assessment

"We focus on the concept of risk assessment for thyroid cancer at different stages of the diagnostic pathway for ...... MTC-medullary thyroid cancer."

Published: Jan 4th, 2020 5:00 PM

Plea for access to new drug for girl diagnosed with brain cancer

"The new drug, ONC201, is being trialled in the USA and Germany but not ... ONC201 has been shown to kill tumour cells in studies overseas but the ..."

Published: Jan 2nd, 2020 8:00 PM

New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals

"She joins from Tmunity Therapeutics, where she also served as chief medical ... At Tmunity, she was responsible for the development of the company's ..."

Published: Jan 1st, 2020 8:00 PM

Video Series Offers Support to Cancer Caregivers

"The American Cancer Society (ACS) created a video series for caregiver support to address their most-asked ... RET-Mutant Medullary Thyroid Cancer"

Published: Dec 31st, 2019 11:56 PM

CURE's Clinical Trial Corner: December 2019

"The trial will enroll 400 patients with advanced or metastatic RET-mutant medullary thyroid cancer who have received no prior systemic therapy for ..."

Published: Dec 31st, 2019 2:00 AM

Lilly opens Phase III trial of highly targeted Loxo drug in thyroid cancer

""This Phase III trial of selpercatinib in patients advanced or metastatic ... The thyroid cancer trial is randomizing patients to receive selpercatinib or ..."

Published: Dec 30th, 2019 9:41 PM

Eli Lilly Opens Phase III Trial for RET-Mutant Medullary Thyroid Cancer

"Selpercatinib is an orally administered drug in clinical development for cancers with abnormalities in the rearranged during transfection (RET) kinase."

Published: Dec 30th, 2019 5:56 PM

Lilly launches late-stage study of LOXO-292 in medullary thyroid cancer

"Eli Lilly (NYSE:LLY) initiates a Phase 3 clinical trial, LIBRETTO-531, evaluating selpercatinib (LOXO-292) in previously untreated patients with ..."

Published: Dec 30th, 2019 4:37 PM

Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer

"Randomized trial will examine selpercatinib against standard of care in 400 patients with advanced or metastatic treatment-naieve RET-mutant..."

Published: Dec 27th, 2019 11:56 PM

First Randomized Phase III Trial Opens for Treatment-Naive RET Fusion-Positive NSCLC

"Breakthrough designations in RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer (MTC), and RETfusion-positive thyroid cancers have ..."

Published: Dec 25th, 2019 6:19 PM

Thyroid Cancer Treatment Market Will Generate New Growth Opportunities in the Next Upcoming ...

"Follicular cancer, medullary cancer, and Anaplastic cancer are different types of thyroid cancers. The treatments which is available for thyroid cancer ..."

Published: Dec 23rd, 2019 6:30 PM

New medical chief at Rubius Therapeutics

"Dr. Coughlin joins Rubius from Tmunity Therapeutics, where she served as CMO and was responsible for the development of Tmunity's CAR-T and ..."

Published: Dec 23rd, 2019 6:02 PM

Rubius Therapeutics Appoints Christina Coughlin, MD, Ph.D., as Chief Medical Officer

"A trained oncologist and immunologist, Dr. Coughlin joins Rubius from Tmunity Therapeutics, Inc., where she served as chief medical officer and was ..."

Published: Dec 18th, 2019 8:56 PM

Natpar(a): A Case in Point for Rare Disease Drugs?

"While the recent recall of injectable recombinant parathyroid hormone (PTH) (Natpara, Takeda) in the United States has grabbed the headlines, the ..."

Published: Dec 18th, 2019 2:56 AM

Eli Lilly Shines With BTK Inhibitor Drug In Treating B-Cell Leukemias And Lymphomas

"It used its drug LOXO-305 to treat B-Cell Leukemias and Lymphomas. ... Eli Lilly's other product from the acquisition of LOXO, known as LOXO-292, ..."

Published: Dec 17th, 2019 10:15 PM

RET Inhibitor Trial Updates at ASCO and ESMO

"... the BLU-667 agent in medullary thyroid cancer predominantly. That, again, showed extremely good response rate, with a total response rate, overall ..."

Published: Dec 17th, 2019 10:03 PM

ESMO 2019 LIBRETTO-001 Trial Updates

"... an update of the LIBRETTO-001 study for differentiated thyroid cancer and medullary thyroid cancer was presented, and the partial response was in ..."

Published: Dec 17th, 2019 9:52 PM

LOXO-292 in Patients With RET-Fusion Lung Cancer

"LOXO-292 in Patients With RET-Fusion Lung Cancer. Insights From: Jacob Sands, MD, Dana-Farber Cancer Institute; Benjamin Besse, MD, PhD, ..."

Published: Dec 17th, 2019 7:05 PM

Turning Point Therapeutics to Participate in 38th Annual JP Morgan Healthcare Conference

"The company's pipeline of drug candidates also includes TPX-0022, ... and TPX-0046, targeting RET and SRC, which is currently being studied in a ..."

Published: Dec 16th, 2019 10:03 PM

Top M&A Deals in 2019

"LOXO-292, a first-in-class oral RET inhibitor that has been granted Breakthrough Therapy designation by the FDA for three indications, with an initial ..."

Published: Dec 13th, 2019 8:14 PM

Blueprint Medicines (BPMC) Up More Than 30% YTD: Here's Why

"Pralsetinib (formerly BLU-667) in being studied in the phase I/II ARROW study evaluating previously-treated patients with receptor tyrosine RET-fusion ..."

Published: Dec 13th, 2019 7:37 PM

Blueprint Medicines (BPMC) Up More Than 30% YTD: Here's Why

"... is being evaluated in several late-stage studies for cancer indications. ... lung cancer (NSCLC) and RET-mutant medullary thyroid carcinoma (MTC)."

Published: Dec 13th, 2019 5:00 PM

Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study

"Lilly Initiates Lung Cancer Study on Selpercatinib: Lilly began a phase III study to evaluate its oral RET inhibitor, selpercatinib/LOXO-292in previously ..."

Published: Dec 12th, 2019 8:33 PM

Lilly Initiates Phase III Lung Cancer Study on RET Inhibitor

"Eli Lilly and Company LLY initiated a phase III LIBRETTO-431 study (NCT04194944) on its oral RET inhibitor, selpercatinib (LOXO-292), ..."

Published: Dec 12th, 2019 7:03 PM

Lilly Initiates Phase III Lung Cancer Study on RET Inhibitor

"Eli Lilly and Company LLY initiated a phase III LIBRETTO-431 study (NCT04194944) on its oral RET inhibitor, selpercatinib (LOXO-292), ..."

Published: Dec 12th, 2019 2:33 PM

Lilly launches first of its kind trial for RET fusion-positive NSCLC

"The LIBRETTO-431 clinical trial is assessing selpercatinib, also known as LOXO-292, for treatment-naiive RET fusion-positive non-small cell lung ..."

Published: Dec 12th, 2019 2:11 AM

Eli Lilly Opens Phase III Trial for RET Fusion-Positive Non-Small Cell Lung Cancer Drug

"The trial will examine the effects of selpercatinib (LOXO-292) in cancer patients who have had no prior treatment for their condition. Participants will be ..."

Published: Dec 11th, 2019 10:48 PM

Lilly Opens First Ever Randomized Phase 3 Clinical Trial in Treatment-Naiive RET Fusion-Positive ...

"Selpercatinib has received breakthrough designations in RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer (MTC) and RET ..."

Published: Dec 11th, 2019 4:48 PM

Lilly opens late-stage RET fusion-positive NSCLC study

"Eli Lilly (NYSE:LLY) launches the Phase 3 LIBRETTO-431 clinical trial for selpercatinib, also known as LOXO-292, for treatment-naiive RET ..."

Published: Dec 11th, 2019 4:37 PM

Lilly Opens First Ever Randomized Phase 3 Clinical Trial in Treatment-Naiive RET Fusion-Positive ...

"Enrolled trial participants will be randomized to receive either selpercatinib or platinum-based (carboplatin or cisplatin) and pemetrexed therapy with ..."

Published: Dec 11th, 2019 7:39 AM

A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing LOXO-292 to Platinum-Based ...

"A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing LOXO-292 to Platinum-Based and Pemetrexed Therapy with or without ..."

Published: Dec 10th, 2019 11:41 AM

HR and Talent Acquisition Manager

"Tmunity Therapeutics is seeking a strong talent acquisition and human resources manager to manage..."

Published: Dec 9th, 2019 8:00 PM

Thermo Fisher (TMO) at a 52-Week High: What's Driving It?

"... Test to identify certain non-small cell lung cancer and thyroid cancer patients who may be treated with Lilly's investigational therapy, LOXO-292."

Published: Dec 9th, 2019 3:40 PM

Executive of the Year: Josh Bilenker, Loxo Oncology

"Another, known as selpercatinib, drew Eli Lilly to negotiate what became an $8 billion buyout of Loxo in the opening days of 2019. Measured from the ..."

Published: Dec 4th, 2019 1:03 AM

Woman with 100 cancerous tumours in her lungs refuses to find out prognosis

"A woman who was diagnosed with cancer when she was just 21 was ... result, but an ultrasound revealed Ashley had medullary thyroid cancer."

Published: Dec 2nd, 2019 10:03 PM

Potential Gene Mutation May Help to Identify Familial Thyroid Cancer

""Thyroid cancer is common and on the rise, and hereditary non-medullary thyroid cancers account for 6%-10% of cases," lead study author Darrin ..."

Published: Dec 2nd, 2019 8:33 PM

Drug Recall in US Causes Hypoparathyroid Patients Extreme Hardship

"The recall of injectable recombinant parathyroid hormone (PTH) (Natpara, Takeda) in the United States over safety concerns about the product is ..."

Published: Nov 28th, 2019 4:25 AM

Wichita nonprofit trying to save clinical trial helping young brain cancer patients

"But that grim outlook is different with the drug ONC201. Ward is among the patients participating in a clinical trial for the drug. He says, statistically, he ..."

Published: Nov 27th, 2019 7:26 PM

Treatments Improve PFS in Thyroid Cancer

"Treatments Improve PFS in Thyroid Cancer ... are another 2 drugs that can delay the progression of disease in patients with medullary thyroid cancer."

Published: Nov 27th, 2019 1:03 AM

Molecular Testing Moves in Front of Systemic Treatment for Certain Thyroid Cancers

"Upfront biomarker testing is now recommended for patients with differentiated thyroid cancer (DTC) or medullary thyroid cancer (MTC) since targeted ..."

Published: Nov 22nd, 2019 10:48 PM

Kansas family hoping for miracle for 5-year-old with inoperable cancer

""We're narrowing in on this ONC201 trial that is out there because it's the only thing that we can see that may give us a shred of hope," Stacey said."

Published: Nov 22nd, 2019 4:13 AM

Olathe family hoping for miracle for 5-year-old with inoperable cancer

""We're narrowing in on this ONC201 trial that is out there because it's the only thing that we can see that may give us a shred of hope," Stacey Sands ..."

Published: Nov 21st, 2019 1:48 AM

LIBRETTO-001 Regimen Overview

"In contrast, selpercatinib is a selective RET inhibitor that very meaningfully hits RET but avoids these other targets that can result in adverse effects in ..."

Published: Nov 21st, 2019 1:37 AM

RET Testing in Papillary and Medullary Thyroid Cancer

"The same is true in medullary thyroid cancer, where both vandetanib and cabozantinib work in patients both with and without RET mutations."

Published: Nov 21st, 2019 1:26 AM

RET Treatment: Novel Compounds to Replace Current TKIs

"Marcia Brose, MD, PhD: In medullary thyroid cancer we have these 2 agents. As I just mentioned in the toxicity discussion, these clearly are not agents ..."

Published: Nov 20th, 2019 7:03 PM

Researchers identify new gene mutation in familial thyroid cancers

""Thyroid cancer is common and on the rise, and hereditary non-medullary thyroid cancers account for six to ten percent of cases," said Bann. "Prior to ..."

Published: Nov 20th, 2019 2:45 AM

RET Fusion, Point Mutation, and Signaling

"It is often found in papillary thyroid cancer in that form. That's the contrast with medullary thyroid cancer, where you'll actually have point mutations."

Published: Nov 20th, 2019 12:41 AM

'Stay tuned:' Neoadjuvant therapy in thyroid cancer still needs research

"... with medullary thyroid cancer who have RET mutations and in those with RET-fusion papillary, poorly differentiated and anaplastic thyroid cancer."

Published: Nov 19th, 2019 7:03 PM

Investigational Drug Shows Promise in Patients with RET-Altered Cancers

"Patients with RET-fusion-positive non-small cell lung cancer (NSCLC) had a high response to LOXO-292 (selpercatinib), according to findings from ..."

Published: Nov 18th, 2019 7:03 PM

How gene-edited white blood cells are helping fight cancer

"... scientists from the University of Pennsylvania, the Parker Institute for Cancer Immunotherapy in San Francisco and Tmunity Therapeutics, a biotech ..."

Published: Nov 12th, 2019 6:33 PM

Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients

"The company's pipeline of drug candidates also includes TPX-0022, ... and TPX-0046, targeting RET and SRC, which is currently being studied in a ..."

Published: Nov 12th, 2019 6:08 PM

New Online Reality Series with Actor, Comedian Billy Gardell Chronicles Type 2 Diabetes ...

"It is not known if Ozempic will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Do not use ..."

Published: Nov 12th, 2019 3:39 AM

Dr. Offin on Targeted Agents in MET- and RET-Altered NSCLC

"Encouragingly, selpercatinib (formerly LOXO-292) and BLU-667 have shown greater tolerability. Although selpercatinib has shown a slightly higher ..."

Published: Nov 11th, 2019 8:04 PM

Orphan Drug Recall Leaves Patients in the Lurch

"And since Takeda's Natpara (parathyroid hormone) injection is the only effective treatment for Shelton, she knew when she received an official Takeda ..."

Published: Nov 10th, 2019 10:02 AM

Current Concepts in Head and Neck Surgery

"Incorporate a multidisciplinary approach in the management of tumors of ... well differentiated/de-differentiated/anaplastic/medullary thyroid cancers, ..."

Published: Nov 10th, 2019 5:08 AM

Biological activity of weekly ONC201 in adult recurrent glioblastoma patients

"ONC201 is a dopamine receptor D2 (DRD2) antagonist that penetrates the blood brain barrier. ONC201 efficacy has been shown in glioblastoma ..."

Published: Nov 9th, 2019 8:32 AM

Thyroid cancer at a glance

"There are four types of thyroid cancer: papillary, follicular, medullary and anaplastic. How serious the illness is and the kind of treatment you get ..."

Published: Nov 8th, 2019 9:17 PM

Next-Generation Sequencing Sets Sights On Rare Mutations in Lung Cancer

"With selpercatinib, as well as BLU-667, there is hope for a better targetable option here. Both medications are well tolerated. Selpercatinib had a bit of ..."

Published: Nov 7th, 2019 3:16 PM

Early Results from First-In-US Trial of CRISPR-Edited Immune Cells for Cancer Patients Suggest ...

"Penn is conducting the ongoing study in cooperation with the Parker Institute for Cancer Immunotherapy (PICI) and Tmunity Therapeutics. "This trial is ..."

Published: Nov 7th, 2019 1:30 PM

Tmunity Raises $75 Million in Series B funding for T-cell Therapies Advancement

"In a new development that must have come as a big boost to the company and the wider industry, Tmunity has managed to raise as much as $75 ..."

Published: Nov 7th, 2019 9:34 AM

InDEPTH with Brad Byrd: Sudden Recall

"Recently, the drug Natpara was recalled by pharmaceutical company, Takada. It's used to treat hypoparathyroidism. Sandy Keneipp, who lives in ..."

Published: Nov 7th, 2019 8:47 AM

Tmunity Therapeutics' $75 million financing tops recent funding news in Philadelphia

"Philadelphia-based therapeutics and genetics company Tmunity Therapeutics has secured $75 million in Series B funding, according to company ..."

Published: Nov 7th, 2019 4:54 AM

Another Biotech Gets Big Funding

"Westlake Village BioPartners' first investment, a T-Cell therapy startup called Tmunity Therapeutics, raised $75 million in Series B financing, the ..."

Published: Nov 6th, 2019 10:15 PM

Advancing the Treatment of Thyroid Cancer With Targeted Therapies

"Advancing the Treatment of Thyroid Cancer With Targeted Therapies ... or well-differentiated metastatic thyroid cancer, and also for medullary thyroid ..."

Published: Nov 6th, 2019 9:16 PM

Research underway on essential genes in medullary thyroid cancer

""If we were to understand the proteome changes during medullary thyroid cancer tumor development, we thought that perhaps we could target it," ..."

Published: Nov 6th, 2019 7:41 PM

Doctors try CRISPR gene editing for cancer, a 1st in the US

"... by the University of Pennsylvania, the Parker Institute for Cancer Immunotherapy in San Francisco, and a biotech company, Tmunity Therapeutics."

Published: Nov 6th, 2019 7:01 PM

Crispr Takes Its First Steps in Editing Genes to Fight Cancer

"The research was paid for by the Parker Institute for Cancer Immunotherapy and the company Tmunity. Some members of the research team, but not ..."

Published: Nov 6th, 2019 6:30 PM

Biotherapeutics company enters partnership to design future clinical programs

"East Norriton-based Tmunity Therapeutics, a private clinical-stage biotherapeutics company focused on next-generation T-cell immunotherapy, ..."

Published: Nov 5th, 2019 5:00 PM

Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery ...

"Planned new drug applications for avapritinib for advanced systemic mastocytosis and pralsetinib for previously treated RET fusion non-small cell lung ..."

Published: Nov 4th, 2019 11:56 PM

Philadelphia life sciences companies team up to advance cancer care

"Two Philadelphia life sciences companies are teaming up to advance cancer care. Tmunity Therapeutics, a developer of next-generation T-cell ..."

Published: Nov 1st, 2019 6:41 PM

FiercePharmaAsia-Takeda's rare disease decline; Astellas-Pandion diabetes deal; I-Mab's ...

"... previous two quarters, thanks to competition facing Shire's legacy hemophilia drugs and a surprise U.S. recall of Natpara. Astellas is paying Pandion ..."

Published: Nov 1st, 2019 3:18 AM

Tmunity Secures $75M in Series B Financing

"Tmunity Therapeutics, a Philadelphia, PA-based T-cell immunotherapy company, closed a $75m Series B financing. The round was led by ..."

Published: Nov 1st, 2019 1:26 AM

Andreessen Horowitz Leads $75 Million Financing for Tmunity Therapeutics

"Tmunity Therapeutics Inc. has raised a $75 million Series B funding led by Andreessen Horowitz to propel a series of cancer-fighting cellular therapies ..."

Published: Oct 31st, 2019 7:48 PM

Exelixis (EXEL) Q3 Earnings Beat on Strong Cabometyx Sales

"Cometriq (cabozantinib capsules), for the treatment of medullary thyroid cancer, generated $4.4 million in net product revenues. Total collaboration ..."

Published: Oct 31st, 2019 6:30 PM

Tmunity aims to be the next big biotech win for Philly, raising $75 million from Silicon Valley

"Tmunity Therapeutics, a four-year-old firm developing cancer treatments based on University of Pennsylvania T-cell immunotherapy, has raised ..."

Published: Oct 31st, 2019 5:49 PM

Hemophilia rivalry eats away at post-Shire Takeda-and its Natpara recall bites, too

"Before Takeda scored its $59 billion Shire takeover, critics pointed out threats to the Irish drugmaker's bread-and-butter hemophilia franchise."

Published: Oct 31st, 2019 4:03 PM

Oz Azam beefs up Tmunity's total raise to $231M as they steer toward human data in the drive to ...

"Oz Azam beefs up Tmunity's total raise to $231M as they steer toward human data in the drive to cell therapy 2.0. The CEO of Tmunity believes that if ..."

Published: Oct 31st, 2019 3:52 PM

Andreessen Horowitz leads $75M round for Tmunity as it eyes phase 2 studies for 2021

"The new funding will bankroll R&D, clinical development and manufacturing both for the vectors that deliver Tmunity's treatments as well as the cell ..."

Published: Oct 30th, 2019 8:00 PM

Early Detection Impacts Treatment Decisions in Thyroid Cancers

"Either way, the role of early detection of thyroid cancer is of utmost ... such as medullary thyroid cancer (MTC), differentiated thyroid cancer (DTC), and ..."

Published: Oct 29th, 2019 4:00 PM

Interpace to Present Data at the ATA Annual Meeting

"... other providers who focus on the diagnosis and treatment of thyroid cancer. ... "Molecular diagnosis of medullary thyroid carcinoma by NGS mutation ..."

Published: Oct 25th, 2019 3:52 PM

Don't Sleep on These 2 Pharmaceutical Stocks

"The acquisition also brought Eli Lilly LOXO-292, a promising cancer treatment that could launch next year, and LOXO-305, another cancer treatment ..."

Published: Oct 23rd, 2019 3:18 PM

Lilly Reports Strong Third-Quarter 2019 Financial Results, Raises 2019 EPS Guidance

"... acute treatment of migraine, a new indication for Taltz, positive data readouts for selpercatinib (LOXO-292) and a negative readout for pegilodecakin ..."

Published: Oct 22nd, 2019 2:56 PM

Eli Lilly Reports Earnings Tomorrow. Here's What to Expect.

"The company has reported some promising data in recent months, including a strong response rate for its drug LOXO-292 in some lung cancer ..."

Published: Oct 21st, 2019 8:33 PM

Bernie urges FDA to swiftly resolve drug recall

"In response to Takeda Pharmaceuticals recalling Natpara, a lifesaving drug used to manage blood calcium levels for people with a rare condition ..."

Published: Oct 21st, 2019 11:22 AM

Vietnamese surgeons succeed in operating on three-year-old with thyroid cancer

"Vietnamese surgeons succeed in operating on three-year-old with thyroid ... on an three-year-old kid with metastasized medullary thyroid cancer."

Published: Oct 19th, 2019 12:18 AM

Bernie Sanders, 2 other lawmakers urge FDA to resolve Natpara shortage

"Takeda recalled Natpara, a treatment for a rare, but potentially fatal calcium-depleting disease, Sept. 5 after it discovered rubber particles in the vials ..."

Published: Oct 18th, 2019 11:02 PM

Leahy, Sanders, Welch Urge FDA to Swiftly Resolve Critical Drug Recall

"Peter Welch (D-Vt.) urged the Food and Drug Administration (FDA) to swiftly resolve the recall of Natpara, a lifesaving drug used to manage blood ..."

Published: Oct 18th, 2019 8:56 PM

LIBRETTO-001: RET-Fusion Positive Metastatic NSCLC

"LOXO-292 is a very selective RET inhibitor. Based on recent phase I/II studies, among over 100 patients with advanced-stage, RET fusion-positive ..."

Published: Oct 18th, 2019 4:48 PM

Ipsen adds Blueprint's FOP rare disease drug to pipeline for $535m

"Blueprint also develops cancer drugs. It is developing avapritinib for certain gastrointestinal tumours, and its BLU-667 is in development for cancers ..."

Published: Oct 14th, 2019 9:24 PM

Blueprint Medicines' Avapritinib Grows to Curb Revenue Reliance

"... cancer (NSCLC) and RET-mutant medullary thyroid carcinoma (MTC). The company plans to submit an NDA for pralsetinib pertaining to the NSCLC ..."

Published: Oct 14th, 2019 9:09 PM

FDA Awards $4.1 Billion In Funding For Rare Disease Research

"The grants will specifically go to research for medullary thyroid carcinoma and Duchenne muscular dystrophy, but these subsequent findings will likely ..."

Published: Oct 14th, 2019 8:22 PM

NextUp: Tmunity Therapeutics Is Pioneering Personalized Cancer Treatments

"Who: Tmunity Therapeutics was founded in 2015 by a team of experienced researchers, including Bruce Blazar, Bruce Levine, Yangbing Zhao, Jim ..."

Published: Oct 14th, 2019 5:56 PM

Eli Lilly Stock Gets 2 Pieces of Good News

"The company, however, has announced some promising data in recent months, including a 68% response rate for its experimental drug LOXO-292 ..."

Published: Oct 12th, 2019 5:22 AM

A pain in the neck

"Two other kinds of thyroid cancer - medullary and undifferentiated, which are extremely rare in that they make for less than one per cent of all thyroid ..."

Published: Oct 10th, 2019 7:37 PM

Lung Cancer Therapy Makes Major Advances

"At the World Conference on Lung Cancer, we saw results with LOXO-292 in a cohort of approximately 105 patients with RET-positive lung cancer."

Published: Oct 10th, 2019 5:00 PM

Precision oncology: Exciting clinical developments and complicated biology

"Drilon and colleagues presented results from the LIBRETTO clinical study of selpercatinib (LOXO-292, Loxo Oncology) in September at International ..."

Published: Oct 9th, 2019 5:11 AM

Coverage Initiated on US-Based Precision Therapy Developer

"... pointed out that H.C. Wainwright and key opinion leaders view the market opportunities for both avapritinib and pralsetinib to be "underappreciated."

Published: Oct 8th, 2019 8:22 PM

FDA awards two grants for natural history studies in rare diseases

"University of Texas MD Anderson Cancer Center (Houston, Texas), Elizabeth Grubbs, prospective study in medullary thyroid carcinoma, ..."

Published: Oct 7th, 2019 6:18 PM

Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit

"... identify certain non-small cell lung cancer (NSCLC) and thyroid cancer patients who may be treated with Lilly's investigational therapy, LOXO-292."

Published: Oct 4th, 2019 9:30 PM

At ESMO, more precision medicines show their worth

"... test group, people with RET-mutant medullary thyroid cancer who had previously received Cometriq (cabozantinib) and/or Caprelsa (vandetanib)."

Published: Oct 4th, 2019 8:32 PM

Precision Medicine for RET Fusion-Positive NSCLC

"Selpercatinib (LOXO-292), a RET kinase inhibitor, demonstrated antitumor activity in the lungs and brain and durable responses with acceptable ..."

Published: Oct 3rd, 2019 7:09 PM

Here's Why You Should Add Thermo Fisher to Your Portfolio

"... identify certain non-small cell lung cancer (NSCLC) and thyroid cancer patients, who may be treated with Lilly's investigational therapy, LOXO-292."

Published: Oct 2nd, 2019 11:56 PM

Eli Lilly and Company's (LLY) Management Presents at Lilly Oncology Update at ESMO 2019 ...

"... mutations occur in approximately 60% of sporadic medullary thyroid cancer, ... As you recall, data in RET fusion positive non-small cell lung cancer ..."

Published: Oct 2nd, 2019 8:56 PM

BioIndiana Hotbed: Home to a Thriving Biopharma Industry

"One of the assets, LOXO-292, hit the mark as a monotherapy for the treatment of RET fusion-positive non-small cell lung cancer in a Phase I/II trial."

Published: Oct 2nd, 2019 3:52 PM

The Alliance for Regenerative Medicine Announces Election of 2020 ARM Officers, Executive ...

"WASHINGTON, D.C., Oct. 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM), the international ..."

Published: Oct 2nd, 2019 6:27 AM

Selpercatinib in RET Fusion-Positive Thyroid Cancer

"Selpercatinib (previously known as LOXO-292) is an oral and selective investigational new agent that is being evaluated for the treatment of patients ..."

Published: Oct 1st, 2019 10:37 PM

Penn spinoff licenses experimental cancer immunotherapy from CHOP

"Penn spinoff Tmunity Therapeutics Inc. has entered into an exclusive license and research collaboration agreement with Children's Hospital of ..."

Published: Oct 1st, 2019 4:48 AM

Lilly's Loxo Bet Pays Off In Thyroid Cancer, A Second Indication For Selpercatinib

"The company reported positive Phase III response rate data weeks after strong results in lung cancer for the RET inhibitor also known as LOXO-292."

Published: Sep 30th, 2019 5:22 PM

Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for ...

"... of wildtype and mutated RET kinases as compared to proxy chemical compounds for investigational RET inhibitors, LOXO-292 and BLU-667."

Published: Sep 30th, 2019 3:47 PM

Eli Lilly Says Selpercatinib Shows 'Demonstrative Efficacy and Safety' in RET-Altered Thyroid ...

"In the RET-mutant medullary thyroid cancer population, selpercatinib achieved a 56% overall response rate (ORR) in patients who had prior treatment ..."

Published: Sep 30th, 2019 2:50 PM

Vantage Esmo 2019 roundup

"Thyroid results strengthen selpercatinib's case. 29 September. As selpercatinib confirms its activity in thyroid cancer, Lilly gears up to prove the Ret ..."

Published: Sep 30th, 2019 10:15 AM

Gemma Collins' weight loss jabs - the risks of the hunger fighting injections revealed

"However, it adds: "It is not known if Victoza will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people."."

Published: Sep 29th, 2019 11:56 PM

Selpercatinib Demonstrates Robust ORR in Thyroid Cancer

"Selpercatinib Demonstrates Robust ORR in Thyroid Cancer ... selpercatinib (formally LOXO-292) in patients with RET-mutant medullary thyroid cancer ..."

Published: Sep 29th, 2019 10:36 PM

Selpercatinib Shows Strong ORR in Thyroid Cancer, FDA Submission Expected

"The highly selective RET inhibitor selpercatinib (formally LOXO-292) demonstrated robust objective response rates (ORR) for patients with ..."

Published: Sep 29th, 2019 7:26 PM

ESMO: Lilly's RET drug shrinks more than half of rare thyroid cancers

"It's a different conversation with non-medullary thyroid cancers: "They are more molecularly diverse in a way that is helpful to our story. Today, BRAF ..."

Published: Sep 26th, 2019 12:18 AM

Eli Lilly Throws Hat In The Ring For Lung Cancer Space, Takes Targeted Treatment Approach

"Eli Lilly announced that it had achieved positive results from a phase 1/2 study using the drug selpercatinib to treat RET fusion-positive non-small cell ..."

Published: Sep 25th, 2019 9:18 PM

What to look out for at ESMO 2019

"At the start of the year, when Eli Lilly (NYSE: LLY) bought Loxo Oncology, the potential of its first-in-class oral RET inhibitor LOXO-292 was central to ..."

Published: Sep 24th, 2019 4:37 AM

Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And ...

"Novel selective RET inhibitors like BLU-667, LOXO-292 and RXDX-105 have been recently investigated in early phase clinical trials showing ..."

Published: Sep 24th, 2019 12:30 AM

Lilly, Bayer's tumor-agnostic cancer drug gets European nod

"Another company, Blueprint Medicines, has a competing RET inhibitor in development, BLU-667 (pralsetinib). Analysts have remarked that the ..."

Published: Sep 23rd, 2019 3:41 PM

Lilly Oncology to Present Robust Data across Its Growing Portfolio at ESMO 2019

"Selpercatinib is being investigated in RET fusion-positive cancers across tumor types and RET-mutant medullary thyroid cancer (MTC). RET fusions ..."

Published: Sep 22nd, 2019 6:18 PM

Thyroid Cancer Awareness Month

"And, unlike many other cancers, the mortality rate for thyroid cancer has ... Papillary (and variants), Follicular (including Hurthle Cell), Medullary and ..."

Published: Sep 20th, 2019 9:18 PM

Patients Who Use Natpara Say They are Suffering After Recall

"In this segment, we talk to Becky Buckman who took part in the clinical trials for Natpara and says the drug is a lifesaver. She is now part of a group of ..."

Published: Sep 20th, 2019 9:07 PM

Drugs in the Pipeline: Non-Small-Cell Lung Cancer

"Several promising drugs for the treatment of lung cancer have been ... papillary thyroid cancer (PTC), RET-mutant medullary thyroid cancer (MTC), ..."

Published: Sep 20th, 2019 7:48 PM

FDA approves Rybelsus (semaglutide), the first GLP-1 analog treatment available in a pill for ...

"These may be symptoms of thyroid cancer. ... It is not known if Rybelsus will cause thyroid tumors or a type of thyroid cancer called medullary thyroid ..."

Published: Sep 20th, 2019 3:41 PM

CHMP Issues Positive Opinion to Expand Trulicity (dulaglutide) Label to Include Results from ...

"It is not known if Trulicity will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Patients should not ..."

Published: Sep 19th, 2019 2:56 PM

Thyroid Cancer: Knowing The Facts This Thyroid Cancer Awareness Month

"A small gland located at the base of the neck, the thyroid is part of our ... People with a family history of thyroid cancer, especially medullary thyroid ..."

Published: Sep 18th, 2019 11:56 PM

Selpercatinib Promising in RET Fusion-Positive NSCLC

"... platinum-based chemotherapy and an anti-PD-1 or anti-PD-L1 therapy; RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, ..."

Published: Sep 18th, 2019 6:41 PM

It's really scary Recall of Natpara leaves patients in limbo"

"Natpara was recalled this month because tiny pieces of rubber from the injector were found in some vials of the drug, which could contaminate the ..."

Published: Sep 18th, 2019 11:23 AM

NorCal patients live in fear after parathyroid drug recall

"People suffering from a rare, but potentially deadly disease are now living in fear after their life-saving medication called Natpara was suddenly ..."

Published: Sep 17th, 2019 12:30 AM

How a Once-Weekly Injection Can Help Manage Type 2 Diabetes

"It is unknown whether BYDUREON BCise causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) in humans, as the human ..."